{ "instance": { "pyxs20230603_s4.htm": { "axisCustom": 0, "axisStandard": 39, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 1319, "http://xbrl.sec.gov/dei/2023": 18 }, "contextCount": 365, "dts": { "calculationLink": { "local": [ "pyxs-20230331_cal.xml" ] }, "definitionLink": { "local": [ "pyxs-20230331_def.xml" ] }, "inline": { "local": [ "pyxs20230603_s4.htm" ] }, "labelLink": { "local": [ "pyxs-20230331_lab.xml" ] }, "presentationLink": { "local": [ "pyxs-20230331_pre.xml" ] }, "schema": { "local": [ "pyxs-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] } }, "elementCount": 618, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2023": 52, "http://pyxisoncology.com/20230331": 7, "http://xbrl.sec.gov/dei/2023": 5, "total": 64 }, "keyCustom": 79, "keyStandard": 296, "memberCustom": 45, "memberStandard": 48, "nsprefix": "pyxs", "nsuri": "http://pyxisoncology.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://pyxisoncology.com/20230331/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "009 - Statement - Consolidated Statements of Operations and Comprehensive Loss", "menuCat": "Statements", "order": "10", "role": "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "shortName": "Consolidated Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": null }, "R100": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "099 - Disclosure - Note 11 - Income Taxes (Details Textual)", "menuCat": "Details", "order": "100", "role": "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-details-textual", "shortName": "Note 11 - Income Taxes (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R101": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100 - Disclosure - Note 11 - Income Taxes - Reconciliation of Effective Income Tax Rate (Details)", "menuCat": "Details", "order": "101", "role": "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-reconciliation-of-effective-income-tax-rate-details", "shortName": "Note 11 - Income Taxes - Reconciliation of Effective Income Tax Rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "3", "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R102": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "101 - Disclosure - Note 11 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)", "menuCat": "Details", "order": "102", "role": "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details", "shortName": "Note 11 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R103": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "102 - Disclosure - Note 11 - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)", "menuCat": "Details", "order": "103", "role": "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-schedule-of-unrecognized-tax-benefits-details", "shortName": "Note 11 - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2020-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R104": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "103 - Disclosure - Note 12 - Net Loss Per Share - Antidilutive Securities (Details)", "menuCat": "Details", "order": "104", "role": "http://pyxisoncology.com/20230331/role/statement-note-12-net-loss-per-share-antidilutive-securities-details", "shortName": "Note 12 - Net Loss Per Share - Antidilutive Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2022-01-01_2022-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-StockCompensationPlanMember", "decimals": "INF", "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R105": { "firstAnchor": { "ancestors": [ "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "104 - Disclosure - Note 13 - 401(k) Plan (Details Textual)", "menuCat": "Details", "order": "105", "role": "http://pyxisoncology.com/20230331/role/statement-note-13-401k-plan-details-textual", "shortName": "Note 13 - 401(k) Plan (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R106": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2023-01-23_ClassOfWarrantOrRightAxis-SecuritiesPurchaseAgreementWarrantMember_SubsequentEventTypeAxis-SubsequentEventMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "105 - Disclosure - Note 14 - Subsequent Events (Details Textual)", "menuCat": "Details", "order": "106", "role": "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events-details-textual", "shortName": "Note 14 - Subsequent Events (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2023-01-23_ClassOfWarrantOrRightAxis-SecuritiesPurchaseAgreementWarrantMember_SubsequentEventTypeAxis-SubsequentEventMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2020-12-31_RestatementAxis-ScenarioPreviouslyReportedMember_StatementEquityComponentsAxis-PreferredStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "010 - Statement - Consolidated Statements of Stockholders' Equity", "menuCat": "Statements", "order": "11", "role": "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity", "shortName": "Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2022-01-01_2022-12-31_StatementEquityComponentsAxis-PreferredStockMember", "decimals": "INF", "lang": null, "name": "pyxs:StockIssuedDuringPeriodSharesBusinessCombinationAndPrivateOfferingFinancingNet", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R12": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "011 - Statement - Consolidated Statements of Stockholders' Equity (Parentheticals)", "menuCat": "Statements", "order": "12", "role": "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity-parentheticals", "shortName": "Consolidated Statements of Stockholders' Equity (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R13": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "012 - Statement - Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "13", "role": "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Note 1 - Organization and Description of the Business", "menuCat": "Notes", "order": "14", "role": "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business", "shortName": "Note 1 - Organization and Description of the Business", "subGroupType": "", "uniqueAnchor": null }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Note 2 - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "15", "role": "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies", "shortName": "Note 2 - Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": null }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Note 3 - Merger (10Q)", "menuCat": "Notes", "order": "16", "role": "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q", "shortName": "Note 3 - Merger (10Q)", "subGroupType": "", "uniqueAnchor": null }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Note 4 - Fair Value Measurement (10Q)", "menuCat": "Notes", "order": "17", "role": "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-10q", "shortName": "Note 4 - Fair Value Measurement (10Q)", "subGroupType": "", "uniqueAnchor": null }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Note 5 - Balance Sheet Components (10 Q)", "menuCat": "Notes", "order": "18", "role": "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-10-q-", "shortName": "Note 5 - Balance Sheet Components (10 Q)", "subGroupType": "", "uniqueAnchor": null }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Note 6 - Stockholder's Equity", "menuCat": "Notes", "order": "19", "role": "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity", "shortName": "Note 6 - Stockholder's Equity", "subGroupType": "", "uniqueAnchor": null }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2023-03-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)", "menuCat": "Statements", "order": "2", "role": "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "shortName": "Condensed Consolidated Balance Sheets (Current Period Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2023-03-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "pyxs:WarrantsTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Note 7 - Public and Private Warrants", "menuCat": "Notes", "order": "20", "role": "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants", "shortName": "Note 7 - Public and Private Warrants", "subGroupType": "", "uniqueAnchor": null }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Note 8 - Equity Plans and Related Equity Activities", "menuCat": "Notes", "order": "21", "role": "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities", "shortName": "Note 8 - Equity Plans and Related Equity Activities", "subGroupType": "", "uniqueAnchor": null }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Note 9 - Commitments and Contingencies", "menuCat": "Notes", "order": "22", "role": "http://pyxisoncology.com/20230331/role/statement-note-9-commitments-and-contingencies", "shortName": "Note 9 - Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": null }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Note 10 - Income Taxes", "menuCat": "Notes", "order": "23", "role": "http://pyxisoncology.com/20230331/role/statement-note-10-income-taxes", "shortName": "Note 10 - Income Taxes", "subGroupType": "", "uniqueAnchor": null }, "R24": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Note 11 - Net Loss Per Share", "menuCat": "Notes", "order": "24", "role": "http://pyxisoncology.com/20230331/role/statement-note-11-net-loss-per-share", "shortName": "Note 11 - Net Loss Per Share", "subGroupType": "", "uniqueAnchor": null }, "R25": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Note 12 - Subsequent Event", "menuCat": "Notes", "order": "25", "role": "http://pyxisoncology.com/20230331/role/statement-note-12-subsequent-event", "shortName": "Note 12 - Subsequent Event", "subGroupType": "", "uniqueAnchor": null }, "R26": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Note 1 - Organization and Description of the Business", "menuCat": "Notes", "order": "26", "role": "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-businessA333C5D9-19D0-4567-932F-9815DE5E9A16", "shortName": "Note 1 - Organization and Description of the Business", "subGroupType": "", "uniqueAnchor": null }, "R27": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Note 2 - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "27", "role": "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies2BD6C28F-50E7-4037-A60B-045979707453", "shortName": "Note 2 - Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": null }, "R28": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Note 3 - Merger", "menuCat": "Notes", "order": "28", "role": "http://pyxisoncology.com/20230331/role/statement-note-3-merger", "shortName": "Note 3 - Merger", "subGroupType": "", "uniqueAnchor": null }, "R29": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Note 4 - Fair Value Measurement", "menuCat": "Notes", "order": "29", "role": "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement", "shortName": "Note 4 - Fair Value Measurement", "subGroupType": "", "uniqueAnchor": null }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "menuCat": "Statements", "order": "3", "role": "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "shortName": "Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Note 5 - Balance Sheet Components", "menuCat": "Notes", "order": "30", "role": "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components", "shortName": "Note 5 - Balance Sheet Components", "subGroupType": "", "uniqueAnchor": null }, "R31": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Note 6 - Lease", "menuCat": "Notes", "order": "31", "role": "http://pyxisoncology.com/20230331/role/statement-note-6-lease", "shortName": "Note 6 - Lease", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Note 7 - Stockholder's Equity", "menuCat": "Notes", "order": "32", "role": "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity", "shortName": "Note 7 - Stockholder's Equity", "subGroupType": "", "uniqueAnchor": null }, "R33": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "pyxs:WarrantsTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Note 8 - Public and Private Warrants", "menuCat": "Notes", "order": "33", "role": "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants", "shortName": "Note 8 - Public and Private Warrants", "subGroupType": "", "uniqueAnchor": null }, "R34": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Note 9 - Equity Plans and Related Equity Activities", "menuCat": "Notes", "order": "34", "role": "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities", "shortName": "Note 9 - Equity Plans and Related Equity Activities", "subGroupType": "", "uniqueAnchor": null }, "R35": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Note 10 - Commitments and Contingencies", "menuCat": "Notes", "order": "35", "role": "http://pyxisoncology.com/20230331/role/statement-note-10-commitments-and-contingencies", "shortName": "Note 10 - Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": null }, "R36": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Note 11 - Income Taxes", "menuCat": "Notes", "order": "36", "role": "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes", "shortName": "Note 11 - Income Taxes", "subGroupType": "", "uniqueAnchor": null }, "R37": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Note 12 - Net Loss Per Share", "menuCat": "Notes", "order": "37", "role": "http://pyxisoncology.com/20230331/role/statement-note-12-net-loss-per-share", "shortName": "Note 12 - Net Loss Per Share", "subGroupType": "", "uniqueAnchor": null }, "R38": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Note 13 - 401(k) Plan", "menuCat": "Notes", "order": "38", "role": "http://pyxisoncology.com/20230331/role/statement-note-13-401k-plan", "shortName": "Note 13 - 401(k) Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Note 14 - Subsequent Events", "menuCat": "Notes", "order": "39", "role": "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events", "shortName": "Note 14 - Subsequent Events", "subGroupType": "", "uniqueAnchor": null }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": null }, "R40": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "pyxs:UnauditedInterimFinancialStatementsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "40", "role": "http://pyxisoncology.com/20230331/role/statement-significant-accounting-policies-policies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "pyxs:UnauditedInterimFinancialStatementsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Note 3 - Merger (10Q) (Tables)", "menuCat": "Tables", "order": "41", "role": "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-tables", "shortName": "Note 3 - Merger (10Q) (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R42": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Note 4 - Fair Value Measurement (10Q) (Tables)", "menuCat": "Tables", "order": "42", "role": "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-10q-tables", "shortName": "Note 4 - Fair Value Measurement (10Q) (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R43": { "firstAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "pyxs:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Note 5 - Balance Sheet Components (10 Q) (Tables)", "menuCat": "Tables", "order": "43", "role": "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-10-q-tables", "shortName": "Note 5 - Balance Sheet Components (10 Q) (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R44": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "pyxs:ScheduleOfConvertiblePreferredStockTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Note 6 - Stockholder's Equity (Tables)", "menuCat": "Tables", "order": "44", "role": "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-tables", "shortName": "Note 6 - Stockholder's Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R45": { "firstAnchor": { "ancestors": [ "pyxs:WarrantsTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Note 7 - Public and Private Warrants (Tables)", "menuCat": "Tables", "order": "45", "role": "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-tables", "shortName": "Note 7 - Public and Private Warrants (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "pyxs:WarrantsTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Note 8 - Equity Plans and Related Equity Activities (Tables)", "menuCat": "Tables", "order": "46", "role": "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-tables", "shortName": "Note 8 - Equity Plans and Related Equity Activities (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R47": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "046 - Disclosure - Note 11 - Net Loss Per Share (Tables)", "menuCat": "Tables", "order": "47", "role": "http://pyxisoncology.com/20230331/role/statement-note-11-net-loss-per-share-tables", "shortName": "Note 11 - Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R48": { "firstAnchor": { "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "047 - Disclosure - Note 3 - Merger (Tables)", "menuCat": "Tables", "order": "48", "role": "http://pyxisoncology.com/20230331/role/statement-note-3-merger-tables", "shortName": "Note 3 - Merger (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R49": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "048 - Disclosure - Note 4 - Fair Value Measurement (Tables)", "menuCat": "Tables", "order": "49", "role": "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-tables", "shortName": "Note 4 - Fair Value Measurement (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2020-12-31_RestatementAxis-ScenarioPreviouslyReportedMember_StatementEquityComponentsAxis-PreferredStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "menuCat": "Statements", "order": "5", "role": "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31_StatementEquityComponentsAxis-RetainedEarningsAppropriatedMember", "decimals": "-3", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "pyxs:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "049 - Disclosure - Note 5 - Balance Sheet Components (Tables)", "menuCat": "Tables", "order": "50", "role": "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-tables", "shortName": "Note 5 - Balance Sheet Components (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R51": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "050 - Disclosure - Note 6 - Lease (Tables)", "menuCat": "Tables", "order": "51", "role": "http://pyxisoncology.com/20230331/role/statement-note-6-lease-tables", "shortName": "Note 6 - Lease (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "pyxs:ScheduleOfConvertiblePreferredStockTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "051 - Disclosure - Note 7 - Stockholder's Equity (Tables)", "menuCat": "Tables", "order": "52", "role": "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-tables", "shortName": "Note 7 - Stockholder's Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R53": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "052 - Disclosure - Note 9 - Equity Plans and Related Equity Activities (Tables)", "menuCat": "Tables", "order": "53", "role": "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-tables", "shortName": "Note 9 - Equity Plans and Related Equity Activities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "053 - Disclosure - Note 11 - Income Taxes (Tables)", "menuCat": "Tables", "order": "54", "role": "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-tables", "shortName": "Note 11 - Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "054 - Disclosure - Note 12 - Net Loss Per Share (Tables)", "menuCat": "Tables", "order": "55", "role": "http://pyxisoncology.com/20230331/role/statement-note-12-net-loss-per-share-tables", "shortName": "Note 12 - Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R56": { "firstAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-02-23_2023-02-23", "decimals": "2", "first": true, "lang": null, "name": "pyxs:WorkforceReductionPercent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "055 - Disclosure - Note 1 - Organization and Description of the Business (Details Textual)", "menuCat": "Details", "order": "56", "role": "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textual", "shortName": "Note 1 - Organization and Description of the Business (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-02-23_2023-02-23", "decimals": "2", "first": true, "lang": null, "name": "pyxs:WorkforceReductionPercent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "056 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)", "menuCat": "Details", "order": "57", "role": "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "shortName": "Note 2 - Summary of Significant Accounting Policies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LesseeLeasesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "INF", "lang": null, "name": "pyxs:MonthlyRent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "057 - Disclosure - Note 3 - Merger (10Q) (Details Textual)", "menuCat": "Details", "order": "58", "role": "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-details-textual", "shortName": "Note 3 - Merger (10Q) (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2022-07-29_BusinessAcquisitionAxis-LegacyApexigenMember", "decimals": "-6", "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAcquiredFromAcquisition", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "058 - Disclosure - Note 3 - Merger - Schedule of Elements of Business Combination (10Q) (Details)", "menuCat": "Details", "order": "59", "role": "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "shortName": "Note 3 - Merger - Schedule of Elements of Business Combination (10Q) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R6": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals)", "menuCat": "Statements", "order": "6", "role": "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited-parentheticals", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R60": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShortTermInvestments", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "059 - Disclosure - Note 4 - Fair Value Measurement (10Q) (Details Textual)", "menuCat": "Details", "order": "60", "role": "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-10q-details-textual", "shortName": "Note 4 - Fair Value Measurement (10Q) (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R61": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2023-03-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060 - Disclosure - Note 4 - Fair Value Measurement - Financial Instruments on Recurring Basis (10Q) (Details)", "menuCat": "Details", "order": "61", "role": "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-10q-details", "shortName": "Note 4 - Fair Value Measurement - Financial Instruments on Recurring Basis (10Q) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R62": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "pyxs:CashAndCashEquivalentsAndDebtSecuritiesAvailableforsaleAmortizedCostToFairValueTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2023-03-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061 - Disclosure - Note 4 - Fair Value Measurement - Estimated Fair Value of Marketable Securities and Gross Unrealized Holding Gains and Losses (10Q) (Details)", "menuCat": "Details", "order": "62", "role": "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-10q-details", "shortName": "Note 4 - Fair Value Measurement - Estimated Fair Value of Marketable Securities and Gross Unrealized Holding Gains and Losses (10Q) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R63": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:GainLossOnSaleOfPropertyPlantEquipment", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "062 - Disclosure - Note 5 - Balance Sheet Components (10 Q) (Details Textual)", "menuCat": "Details", "order": "63", "role": "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-10-q-details-textual", "shortName": "Note 5 - Balance Sheet Components (10 Q) (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember", "decimals": "INF", "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentDisposals", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "pyxs:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "pyxs:PrepaidClinicalDevelopmentExpenses", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "063 - Disclosure - Note 5 - Balance Sheet Components - Summary of Prepaid Expenses and Other Current Assets (10Q) (Details)", "menuCat": "Details", "order": "64", "role": "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-prepaid-expenses-and-other-current-assets-10q-details", "shortName": "Note 5 - Balance Sheet Components - Summary of Prepaid Expenses and Other Current Assets (10Q) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "pyxs:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2023-03-31", "decimals": "-3", "lang": null, "name": "pyxs:OtherPrepaidExpensesAndCurrentAssetsIncludingDeferredFinancingCosts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "064 - Disclosure - Note 5 - Balance Sheet Components - Summary of Property, Plant and Equipment (10Q) (Details)", "menuCat": "Details", "order": "65", "role": "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-10q-details", "shortName": "Note 5 - Balance Sheet Components - Summary of Property, Plant and Equipment (10Q) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R66": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "pyxs:AccruedClinicalTrialAndManufacturingCosts", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "065 - Disclosure - Note 5 - Balance Sheet Components - Summary of Accrued Liabilities (10Q) (Details)", "menuCat": "Details", "order": "66", "role": "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-accrued-liabilities-10q-details", "shortName": "Note 5 - Balance Sheet Components - Summary of Accrued Liabilities (10Q) (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R67": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "066 - Disclosure - Note 6 - Stockholder's Equity (Details Textual)", "menuCat": "Details", "order": "67", "role": "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "shortName": "Note 6 - Stockholder's Equity (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2022-07-29_2022-07-29_InvestmentTypeAxis-TwoThousandTwentyTwoPIPEMember", "decimals": "-6", "lang": null, "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesOutstanding", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "067 - Disclosure - Note 6 - Stockholder's Equity - Summary of Convertible Preferred Stock (Details)", "menuCat": "Details", "order": "68", "role": "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-summary-of-convertible-preferred-stock-details", "shortName": "Note 6 - Stockholder's Equity - Summary of Convertible Preferred Stock (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R69": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "068 - Disclosure - Note 6 - Stockholder's Equity - Summary of Common Stock Reserved for Issuance (Details)", "menuCat": "Details", "order": "69", "role": "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-summary-of-common-stock-reserved-for-issuance-details", "shortName": "Note 6 - Stockholder's Equity - Summary of Common Stock Reserved for Issuance (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "7", "role": "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "069 - Disclosure - Note 7 - Public and Private Warrants (Details Textual)", "menuCat": "Details", "order": "70", "role": "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-details-textual", "shortName": "Note 7 - Public and Private Warrants (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "pyxs:WarrantsTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2023-03-31_ClassOfWarrantOrRightAxis-PublicWarrantsMember", "decimals": "-5", "lang": null, "name": "us-gaap:WarrantsAndRightsOutstanding", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "pyxs:WarrantsTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2023-01-30_ClassOfWarrantOrRightAxis-PublicWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "070 - Disclosure - Note 7 - Public and Private Warrants - Measurement Inputs and Valuation Techniques of Warrants (Details)", "menuCat": "Details", "order": "71", "role": "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-measurement-inputs-and-valuation-techniques-of-warrants-details", "shortName": "Note 7 - Public and Private Warrants - Measurement Inputs and Valuation Techniques of Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "pyxs:WarrantsTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2023-01-30_ClassOfWarrantOrRightAxis-PublicWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "071 - Disclosure - Note 8 - Equity Plans and Related Equity Activities (Details Textual)", "menuCat": "Details", "order": "72", "role": "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "shortName": "Note 8 - Equity Plans and Related Equity Activities (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2022-01-01_2022-03-31", "decimals": "INF", "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "072 - Disclosure - Note 8 - Equity Plans and Related Equity Activities - Stock-based Compensation Expense (Details)", "menuCat": "Details", "order": "73", "role": "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-stockbased-compensation-expense-details", "shortName": "Note 8 - Equity Plans and Related Equity Activities - Stock-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R74": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31_OtherCommitmentsAxis-ClinicalCollaborationsMember_RangeAxis-MaximumMember", "decimals": "-5", "first": true, "lang": null, "name": "pyxs:ClinicalMilestonesPaymentInCashAndSharesOfCommonStock", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "073 - Disclosure - Note 9 - Commitments and Contingencies (Details Textual)", "menuCat": "Details", "order": "74", "role": "http://pyxisoncology.com/20230331/role/statement-note-9-commitments-and-contingencies-details-textual", "shortName": "Note 9 - Commitments and Contingencies (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R75": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "074 - Disclosure - Note 10 - Income Taxes (Details Textual)", "menuCat": "Details", "order": "75", "role": "http://pyxisoncology.com/20230331/role/statement-note-10-income-taxes-details-textual", "shortName": "Note 10 - Income Taxes (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R76": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "075 - Disclosure - Note 11 - Net Loss Per Share - Antidilutive Securities (Details)", "menuCat": "Details", "order": "76", "role": "http://pyxisoncology.com/20230331/role/statement-note-11-net-loss-per-share-antidilutive-securities-details", "shortName": "Note 11 - Net Loss Per Share - Antidilutive Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember", "decimals": "INF", "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DeferredChargesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2022-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "076 - Disclosure - Note 1 - Organization and Description of the Business (Details Textual)", "menuCat": "Details", "order": "77", "role": "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textualB5161F24-A199-4D9A-9D11-680B80832079", "shortName": "Note 1 - Organization and Description of the Business (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2022-07-29_2022-07-29_InvestmentTypeAxis-PIPEInvestmentMember", "decimals": "-6", "lang": null, "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "077 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)", "menuCat": "Details", "order": "78", "role": "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9", "shortName": "Note 2 - Summary of Significant Accounting Policies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DeferredChargesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2021-12-31", "decimals": "-5", "lang": null, "name": "us-gaap:DeferredCostsCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "078 - Disclosure - Note 3 - Merger (Details Textual)", "menuCat": "Details", "order": "79", "role": "http://pyxisoncology.com/20230331/role/statement-note-3-merger-details-textual", "shortName": "Note 3 - Merger (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R8": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "007 - Statement - Consolidated Balance Sheets", "menuCat": "Statements", "order": "8", "role": "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:OperatingLeaseLiabilityNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAcquiredFromAcquisition", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "079 - Disclosure - Note 3 - Merger - Schedule of Elements of Business Combination (Details)", "menuCat": "Details", "order": "80", "role": "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details", "shortName": "Note 3 - Merger - Schedule of Elements of Business Combination (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R81": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DerivativesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilities", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080 - Disclosure - Note 4 - Fair Value Measurement (Details Textual)", "menuCat": "Details", "order": "81", "role": "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-details-textual", "shortName": "Note 4 - Fair Value Measurement (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R82": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2023-03-31_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "081 - Disclosure - Note 4 - Fair Value Measurement - Financial Instruments on Recurring Basis (Details)", "menuCat": "Details", "order": "82", "role": "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-details", "shortName": "Note 4 - Fair Value Measurement - Financial Instruments on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2021-12-31_FairValueByLiabilityClassAxis-PreferredStockWarrantLiabilityMember_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember", "decimals": "-3", "lang": null, "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "pyxs:CashAndCashEquivalentsAndDebtSecuritiesAvailableforsaleAmortizedCostToFairValueTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2023-03-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "082 - Disclosure - Note 4 - Fair Value Measurement - Estimated Fair Value of Marketable Securities and Gross Unrealized Holding Gains and Losses (Details)", "menuCat": "Details", "order": "83", "role": "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-details", "shortName": "Note 4 - Fair Value Measurement - Estimated Fair Value of Marketable Securities and Gross Unrealized Holding Gains and Losses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2021-12-31_FinancialInstrumentAxis-CommercialPaperNotIncludedWithCashAndCashEquivalentsMember", "decimals": "-3", "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "083 - Disclosure - Note 5 - Balance Sheet Components (Details Textual)", "menuCat": "Details", "order": "84", "role": "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-details-textual", "shortName": "Note 5 - Balance Sheet Components (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R85": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "pyxs:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "pyxs:PrepaidClinicalDevelopmentExpenses", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "084 - Disclosure - Note 5 - Balance Sheet Components - Summary of Prepaid Expenses and Other Current Assets (Details)", "menuCat": "Details", "order": "85", "role": "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-prepaid-expenses-and-other-current-assets-details", "shortName": "Note 5 - Balance Sheet Components - Summary of Prepaid Expenses and Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "pyxs:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "lang": null, "name": "pyxs:DeferredFinancingCosts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "085 - Disclosure - Note 5 - Balance Sheet Components - Summary of Property, Plant and Equipment (Details)", "menuCat": "Details", "order": "86", "role": "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-details", "shortName": "Note 5 - Balance Sheet Components - Summary of Property, Plant and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R87": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "pyxs:AccruedClinicalTrialAndManufacturingCosts", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "086 - Disclosure - Note 5 - Balance Sheet Components - Summary of Accrued Liabilities (Details)", "menuCat": "Details", "order": "87", "role": "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-accrued-liabilities-details", "shortName": "Note 5 - Balance Sheet Components - Summary of Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R88": { "firstAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2022-12-31", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "087 - Disclosure - Note 6 - Lease (Details Textual)", "menuCat": "Details", "order": "88", "role": "http://pyxisoncology.com/20230331/role/statement-note-6-lease-details-textual", "shortName": "Note 6 - Lease (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2022-12-31", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "088 - Disclosure - Note 6 - Lease - Maturity of Operating Lease (Details)", "menuCat": "Details", "order": "89", "role": "http://pyxisoncology.com/20230331/role/statement-note-6-lease-maturity-of-operating-lease-details", "shortName": "Note 6 - Lease - Maturity of Operating Lease (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R9": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "008 - Statement - Consolidated Balance Sheets (Parentheticals)", "menuCat": "Statements", "order": "9", "role": "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets-parentheticals", "shortName": "Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R90": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "089 - Disclosure - Note 7 - Stockholder's Equity (Details Textual)", "menuCat": "Details", "order": "90", "role": "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual", "shortName": "Note 7 - Stockholder's Equity (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2022-12-31_RelatedPartyTransactionsByRelatedPartyAxis-LincolnParkCapitalFundMember", "decimals": "-5", "lang": null, "name": "pyxs:CommonStockLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesOutstanding", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090 - Disclosure - Note 7 - Stockholder's Equity - Summary of Convertible Preferred Stock (Details)", "menuCat": "Details", "order": "91", "role": "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-summary-of-convertible-preferred-stock-details", "shortName": "Note 7 - Stockholder's Equity - Summary of Convertible Preferred Stock (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R92": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091 - Disclosure - Note 7 - Stockholder's Equity - Summary of Common Stock Reserved for Issuance (Details)", "menuCat": "Details", "order": "92", "role": "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-summary-of-common-stock-reserved-for-issuance-details", "shortName": "Note 7 - Stockholder's Equity - Summary of Common Stock Reserved for Issuance (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R93": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "092 - Disclosure - Note 8 - Public and Private Warrants (Details Textual)", "menuCat": "Details", "order": "93", "role": "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants-details-textual", "shortName": "Note 8 - Public and Private Warrants (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R94": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "093 - Disclosure - Note 9 - Equity Plans and Related Equity Activities (Details Textual)", "menuCat": "Details", "order": "94", "role": "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual", "shortName": "Note 9 - Equity Plans and Related Equity Activities (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2022-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "094 - Disclosure - Note 9 - Equity Plans and Related Equity Activities - Stock-based Compensation Expense (Details)", "menuCat": "Details", "order": "95", "role": "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-stockbased-compensation-expense-details", "shortName": "Note 9 - Equity Plans and Related Equity Activities - Stock-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R96": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2022-01-01_2022-12-31_PlanNameAxis-EquityStockPurchasePlanMember", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "095 - Disclosure - Note 9 - Equity Plans and Related Equity Activities - Schedule of Valuation Assumptions of Stock Options (Details)", "menuCat": "Details", "order": "96", "role": "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-schedule-of-valuation-assumptions-of-stock-options-details", "shortName": "Note 9 - Equity Plans and Related Equity Activities - Schedule of Valuation Assumptions of Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2022-01-01_2022-12-31_PlanNameAxis-EquityStockPurchasePlanMember", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R97": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "096 - Disclosure - Note 9 - Equity Plans and Related Equity Activities - Summary of Activities Under the Plans (Details)", "menuCat": "Details", "order": "97", "role": "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details", "shortName": "Note 9 - Equity Plans and Related Equity Activities - Summary of Activities Under the Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R98": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "097 - Disclosure - Note 9 - Equity Plans and Related Equity Activities - Exercise Price Range of Options (Details)", "menuCat": "Details", "order": "98", "role": "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-exercise-price-range-of-options-details", "shortName": "Note 9 - Equity Plans and Related Equity Activities - Exercise Price Range of Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "i_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R99": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "pyxs20230603_s4.htm", "contextRef": "d_2023-01-01_2023-03-31_OtherCommitmentsAxis-ClinicalCollaborationsMember_RangeAxis-MaximumMember", "decimals": "-5", "first": true, "lang": null, "name": "pyxs:ClinicalMilestonesPaymentInCashAndSharesOfCommonStock", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "098 - Disclosure - Note 10 - Commitments and Contingencies (Details Textual)", "menuCat": "Details", "order": "99", "role": "http://pyxisoncology.com/20230331/role/statement-note-10-commitments-and-contingencies-details-textual", "shortName": "Note 10 - Commitments and Contingencies (Details Textual)", "subGroupType": "details", "uniqueAnchor": null } }, "segmentCount": 103, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r762" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets-parentheticals", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://pyxisoncology.com/20230331/role/statement-document-and-entity-information", "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business", "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textualB5161F24-A199-4D9A-9D11-680B80832079", "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-businessA333C5D9-19D0-4567-932F-9815DE5E9A16", "http://pyxisoncology.com/20230331/role/statement-note-10-commitments-and-contingencies", "http://pyxisoncology.com/20230331/role/statement-note-10-commitments-and-contingencies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-10-income-taxes", "http://pyxisoncology.com/20230331/role/statement-note-10-income-taxes-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-reconciliation-of-effective-income-tax-rate-details", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-schedule-of-unrecognized-tax-benefits-details", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-tables", "http://pyxisoncology.com/20230331/role/statement-note-11-net-loss-per-share", "http://pyxisoncology.com/20230331/role/statement-note-11-net-loss-per-share-antidilutive-securities-details", "http://pyxisoncology.com/20230331/role/statement-note-11-net-loss-per-share-tables", "http://pyxisoncology.com/20230331/role/statement-note-12-net-loss-per-share", "http://pyxisoncology.com/20230331/role/statement-note-12-net-loss-per-share-antidilutive-securities-details", "http://pyxisoncology.com/20230331/role/statement-note-12-net-loss-per-share-tables", "http://pyxisoncology.com/20230331/role/statement-note-12-subsequent-event", "http://pyxisoncology.com/20230331/role/statement-note-13-401k-plan", "http://pyxisoncology.com/20230331/role/statement-note-13-401k-plan-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events", "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies2BD6C28F-50E7-4037-A60B-045979707453", "http://pyxisoncology.com/20230331/role/statement-note-3-merger", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-tables", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-tables", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-10q", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-10q-tables", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-tables", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-10-q-", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-10-q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-10-q-tables", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-accrued-liabilities-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-accrued-liabilities-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-prepaid-expenses-and-other-current-assets-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-prepaid-expenses-and-other-current-assets-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-tables", "http://pyxisoncology.com/20230331/role/statement-note-6-lease", "http://pyxisoncology.com/20230331/role/statement-note-6-lease-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-6-lease-maturity-of-operating-lease-details", "http://pyxisoncology.com/20230331/role/statement-note-6-lease-tables", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-summary-of-common-stock-reserved-for-issuance-details", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-summary-of-convertible-preferred-stock-details", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-tables", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-measurement-inputs-and-valuation-techniques-of-warrants-details", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-tables", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-summary-of-common-stock-reserved-for-issuance-details", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-summary-of-convertible-preferred-stock-details", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-tables", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-stockbased-compensation-expense-details", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-tables", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-commitments-and-contingencies", "http://pyxisoncology.com/20230331/role/statement-note-9-commitments-and-contingencies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-exercise-price-range-of-options-details", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-schedule-of-valuation-assumptions-of-stock-options-details", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-stockbased-compensation-expense-details", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-tables", "http://pyxisoncology.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r762" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r763" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r762" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r762" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r762" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r762" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets-parentheticals", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://pyxisoncology.com/20230331/role/statement-document-and-entity-information", "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business", "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textualB5161F24-A199-4D9A-9D11-680B80832079", "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-businessA333C5D9-19D0-4567-932F-9815DE5E9A16", "http://pyxisoncology.com/20230331/role/statement-note-10-commitments-and-contingencies", "http://pyxisoncology.com/20230331/role/statement-note-10-commitments-and-contingencies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-10-income-taxes", "http://pyxisoncology.com/20230331/role/statement-note-10-income-taxes-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-reconciliation-of-effective-income-tax-rate-details", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-schedule-of-unrecognized-tax-benefits-details", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-tables", "http://pyxisoncology.com/20230331/role/statement-note-11-net-loss-per-share", "http://pyxisoncology.com/20230331/role/statement-note-11-net-loss-per-share-antidilutive-securities-details", "http://pyxisoncology.com/20230331/role/statement-note-11-net-loss-per-share-tables", "http://pyxisoncology.com/20230331/role/statement-note-12-net-loss-per-share", "http://pyxisoncology.com/20230331/role/statement-note-12-net-loss-per-share-antidilutive-securities-details", "http://pyxisoncology.com/20230331/role/statement-note-12-net-loss-per-share-tables", "http://pyxisoncology.com/20230331/role/statement-note-12-subsequent-event", "http://pyxisoncology.com/20230331/role/statement-note-13-401k-plan", "http://pyxisoncology.com/20230331/role/statement-note-13-401k-plan-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events", "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies2BD6C28F-50E7-4037-A60B-045979707453", "http://pyxisoncology.com/20230331/role/statement-note-3-merger", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-tables", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-tables", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-10q", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-10q-tables", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-tables", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-10-q-", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-10-q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-10-q-tables", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-accrued-liabilities-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-accrued-liabilities-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-prepaid-expenses-and-other-current-assets-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-prepaid-expenses-and-other-current-assets-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-tables", "http://pyxisoncology.com/20230331/role/statement-note-6-lease", "http://pyxisoncology.com/20230331/role/statement-note-6-lease-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-6-lease-maturity-of-operating-lease-details", "http://pyxisoncology.com/20230331/role/statement-note-6-lease-tables", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-summary-of-common-stock-reserved-for-issuance-details", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-summary-of-convertible-preferred-stock-details", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-tables", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-measurement-inputs-and-valuation-techniques-of-warrants-details", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-tables", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-summary-of-common-stock-reserved-for-issuance-details", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-summary-of-convertible-preferred-stock-details", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-tables", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-stockbased-compensation-expense-details", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-tables", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-commitments-and-contingencies", "http://pyxisoncology.com/20230331/role/statement-note-9-commitments-and-contingencies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-exercise-price-range-of-options-details", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-schedule-of-valuation-assumptions-of-stock-options-details", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-stockbased-compensation-expense-details", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-tables", "http://pyxisoncology.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "pyxs_AccruedClinicalTrialAndManufacturingCosts": { "auth_ref": [], "calculation": { "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-accrued-liabilities-10q-details": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-accrued-liabilities-details": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accrued clinical trial and manufacturing costs.", "label": "Accrued clinical trial and manufacturing costs" } } }, "localname": "AccruedClinicalTrialAndManufacturingCosts", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-accrued-liabilities-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-accrued-liabilities-details" ], "xbrltype": "monetaryItemType" }, "pyxs_AccruedTransactionCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accrued transaction costs.", "label": "pyxs_AccruedTransactionCosts", "terseLabel": "Accrued Transaction Costs" } } }, "localname": "AccruedTransactionCosts", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "pyxs_AdditionalVendorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents additional vendor.", "label": "Additional Vendor [Member]" } } }, "localname": "AdditionalVendorMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies2BD6C28F-50E7-4037-A60B-045979707453" ], "xbrltype": "domainItemType" }, "pyxs_AnnualIncreaseInSharesReservedForIssuanceAsAPercentageOfCommonSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents annual increase in shares reserved for issuance as a percentage of common shares outstanding.", "label": "pyxs_AnnualIncreaseInSharesReservedForIssuanceAsAPercentageOfCommonSharesOutstanding", "terseLabel": "Annual Increase in Shares Reserved For Issuance as A Percentage of Common Shares Outstanding" } } }, "localname": "AnnualIncreaseInSharesReservedForIssuanceAsAPercentageOfCommonSharesOutstanding", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "percentItemType" }, "pyxs_AnotherVendorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents another vendor.", "label": "Another Vendor [Member]" } } }, "localname": "AnotherVendorMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies2BD6C28F-50E7-4037-A60B-045979707453" ], "xbrltype": "domainItemType" }, "pyxs_AsPerCaresActPermitsOperatingLossCarryforwardsAndCarrybaksToOffsetPercentageOfTaxableIncome": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of taxable income as per CARES Act permits for operating loss carry forwards and carry backs to offset.", "label": "pyxs_AsPerCaresActPermitsOperatingLossCarryforwardsAndCarrybaksToOffsetPercentageOfTaxableIncome", "terseLabel": "As Per CARES Act Permits, Operating Loss Carryforwards and Carrybaks to Offset, Percentage of Taxable Income" } } }, "localname": "AsPerCaresActPermitsOperatingLossCarryforwardsAndCarrybaksToOffsetPercentageOfTaxableIncome", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "percentItemType" }, "pyxs_BusinessCombinationAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Business Combination Agreement.", "label": "Business Combination Agreement [Member]" } } }, "localname": "BusinessCombinationAgreementMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textualB5161F24-A199-4D9A-9D11-680B80832079", "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-businessA333C5D9-19D0-4567-932F-9815DE5E9A16" ], "xbrltype": "domainItemType" }, "pyxs_BusinessCombinationAndPrivateOffering": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of business combination and private offering.", "label": "Merger and private offering for the year ended December 31, 2022" } } }, "localname": "BusinessCombinationAndPrivateOffering", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details" ], "xbrltype": "monetaryItemType" }, "pyxs_BusinessCombinationAndPrivateOfferingShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in business combination and private offering.", "label": "Business combination and private offering shares (in shares)" } } }, "localname": "BusinessCombinationAndPrivateOfferingShares", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details" ], "xbrltype": "sharesItemType" }, "pyxs_BusinessCombinationDirectAndIncrementalCostsRelatedToEquityIssuance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct and incremental costs related to equity issuance under business combination.", "label": "pyxs_BusinessCombinationDirectAndIncrementalCostsRelatedToEquityIssuance", "terseLabel": "Business Combination, Direct and Incremental Costs Related to Equity Issuance" } } }, "localname": "BusinessCombinationDirectAndIncrementalCostsRelatedToEquityIssuance", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-details-textual" ], "xbrltype": "monetaryItemType" }, "pyxs_BusinessCombinationNetAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net asset value of business combination.", "label": "pyxs_BusinessCombinationNetAsset", "negatedLabel": "Plus: net assets of BCAC" } } }, "localname": "BusinessCombinationNetAsset", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details" ], "xbrltype": "monetaryItemType" }, "pyxs_CashAndCashEquivalentsAndDebtSecuritiesAvailableforsaleAmortizedCostToFairValueTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cash and cash equivalents and debt securities available-for-sale amortized cost to fair value.", "label": "Cash and Cash Equivalents and Debt Securities, Available-for-sale, Amortized Cost to Fair Value [Table Text Block]" } } }, "localname": "CashAndCashEquivalentsAndDebtSecuritiesAvailableforsaleAmortizedCostToFairValueTableTextBlock", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-10q-tables", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-tables" ], "xbrltype": "textBlockItemType" }, "pyxs_CashAndCashEquivalentsUnrealizedGains": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents accumulated gross unrealized gain of cash and cash equivalents.", "label": "Cash equivalents unrealized gains" } } }, "localname": "CashAndCashEquivalentsUnrealizedGains", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-details" ], "xbrltype": "monetaryItemType" }, "pyxs_CashAndCashEquivalentsUnrealizedLoss": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of unrealized loss from cash and cash equivalents.", "label": "pyxs_CashAndCashEquivalentsUnrealizedLoss", "negatedLabel": "cash equivalents, unrealized loss" } } }, "localname": "CashAndCashEquivalentsUnrealizedLoss", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-details" ], "xbrltype": "monetaryItemType" }, "pyxs_CashFeePercentageOfGrossProceedsFromSaleOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amount of cash fee as a percentage of gross proceeds from sale of shares.", "label": "pyxs_CashFeePercentageOfGrossProceedsFromSaleOfShares", "terseLabel": "Cash Fee, Percentage of Gross Proceeds from Sale of Shares" } } }, "localname": "CashFeePercentageOfGrossProceedsFromSaleOfShares", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual" ], "xbrltype": "percentItemType" }, "pyxs_ClassOfWarrantOrRightExercisePricePercentageOfPricePaid": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding as a percentage of price paid.", "label": "pyxs_ClassOfWarrantOrRightExercisePricePercentageOfPricePaid", "terseLabel": "Class of Warrant or Right, Exercise Price, Percentage of Price Paid" } } }, "localname": "ClassOfWarrantOrRightExercisePricePercentageOfPricePaid", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events-details-textual" ], "xbrltype": "percentItemType" }, "pyxs_ClassOfWarrantOrRightIssued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Number of warrants or right issued during the period.", "label": "pyxs_ClassOfWarrantOrRightIssued", "terseLabel": "Class of Warrant or Right, Issued" } } }, "localname": "ClassOfWarrantOrRightIssued", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants-details-textual" ], "xbrltype": "monetaryItemType" }, "pyxs_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents threshold consecutive trading days for redemption of warrants or rights.", "label": "pyxs_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays", "terseLabel": "Class Of Warrant or Right, Redemption of Warrants or Rights, Threshold Consecutive Trading Days (Day)" } } }, "localname": "ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdConsecutiveTradingDays", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants-details-textual" ], "xbrltype": "durationItemType" }, "pyxs_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents threshold trading days for redemption of warrants or rights.", "label": "pyxs_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays", "terseLabel": "Class of Warrant or Right, Redemption of Warrants or Rights, Threshold Trading Days (Day)" } } }, "localname": "ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsThresholdTradingDays", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants-details-textual" ], "xbrltype": "durationItemType" }, "pyxs_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redemption price of warrants or rights.", "label": "pyxs_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights", "terseLabel": "Class Of Warrant or Right, Redemption Price of Warrants or Rights (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants-details-textual" ], "xbrltype": "perShareItemType" }, "pyxs_ClassOfWarrantsOrRightsIssuancePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance price of class of warrants or rights.", "label": "pyxs_ClassOfWarrantsOrRightsIssuancePrice", "terseLabel": "Class of Warrants or Rights, Issuance Price (in dollars per share)" } } }, "localname": "ClassOfWarrantsOrRightsIssuancePrice", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events-details-textual" ], "xbrltype": "perShareItemType" }, "pyxs_ClinicalCollaborationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents clinical collaborations.", "label": "Clinical Collaborations [Member]" } } }, "localname": "ClinicalCollaborationsMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-10-commitments-and-contingencies", "http://pyxisoncology.com/20230331/role/statement-note-10-commitments-and-contingencies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-commitments-and-contingencies", "http://pyxisoncology.com/20230331/role/statement-note-9-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "pyxs_ClinicalMilestonesPaymentInCashAndSharesOfCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of payment in cash and common stock shares for achievement of clinical milestones.", "label": "pyxs_ClinicalMilestonesPaymentInCashAndSharesOfCommonStock", "terseLabel": "Clinical Milestones Payment in Cash and Shares of Common Stock" } } }, "localname": "ClinicalMilestonesPaymentInCashAndSharesOfCommonStock", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-10-commitments-and-contingencies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "pyxs_CommitmentSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents commitment shares.", "label": "Commitment Shares [Member]" } } }, "localname": "CommitmentSharesMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "pyxs_CommonStockLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability to issue common stock.", "label": "pyxs_CommonStockLiability", "terseLabel": "Common Stock Liability" } } }, "localname": "CommonStockLiability", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "pyxs_CommonStockRepresentativeShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of representative shares.", "label": "BCAC Representative shares (in shares)" } } }, "localname": "CommonStockRepresentativeShares", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details" ], "xbrltype": "sharesItemType" }, "pyxs_CommonStockShareAfterBusinessCombination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding after business combination.", "label": "Total shares of common stock immediately after merger (in shares)" } } }, "localname": "CommonStockShareAfterBusinessCombination", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details" ], "xbrltype": "sharesItemType" }, "pyxs_CommonStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of common stock shares.", "label": "Balance as of December 31, 2020 (in shares)" } } }, "localname": "CommonStockShares", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details" ], "xbrltype": "sharesItemType" }, "pyxs_CommonStockSharesEffectedForExchangeRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of common stock shares issued effected for exchange ratio.", "label": "Total Legacy Apexigen shares as of July 29, 2022 (in shares)", "terseLabel": "Balance as of December 31, 2020 (in shares)" } } }, "localname": "CommonStockSharesEffectedForExchangeRatio", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details" ], "xbrltype": "sharesItemType" }, "pyxs_CommonStockSharesOutstandingPriorToConversion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding prior to conversion.", "label": "Legacy Apexigen shares (in shares)" } } }, "localname": "CommonStockSharesOutstandingPriorToConversion", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details" ], "xbrltype": "sharesItemType" }, "pyxs_CommonStockSponsorShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of sponsor shares.", "label": "BCAC Sponsor shares (in shares)" } } }, "localname": "CommonStockSponsorShares", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details" ], "xbrltype": "sharesItemType" }, "pyxs_CommonStockWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents common stock warrants.", "label": "Common Stock Warrants [Member]" } } }, "localname": "CommonStockWarrantsMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-summary-of-common-stock-reserved-for-issuance-details", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-summary-of-common-stock-reserved-for-issuance-details" ], "xbrltype": "domainItemType" }, "pyxs_ConcentrationRiskCreditRiskOffBalanceSheetAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Off balance sheet amount for concentration of credit risk.", "label": "pyxs_ConcentrationRiskCreditRiskOffBalanceSheetAmount", "terseLabel": "Concentration Risk, Credit Risk, Off Balance Sheet Amount" } } }, "localname": "ConcentrationRiskCreditRiskOffBalanceSheetAmount", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9" ], "xbrltype": "monetaryItemType" }, "pyxs_ConvertibleAndNonconvertibleUnsecuredPromissoryNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents convertible and non-convertible unsecured promissory notes.", "label": "Convertible and Non-convertible Unsecured Promissory Notes [Member]" } } }, "localname": "ConvertibleAndNonconvertibleUnsecuredPromissoryNotesMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textualB5161F24-A199-4D9A-9D11-680B80832079", "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-businessA333C5D9-19D0-4567-932F-9815DE5E9A16", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "pyxs_DeferredFinancingCosts": { "auth_ref": [], "calculation": { "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-prepaid-expenses-and-other-current-assets-details": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred financing costs as of balance sheet date.", "label": "Deferred financing costs" } } }, "localname": "DeferredFinancingCosts", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-prepaid-expenses-and-other-current-assets-details" ], "xbrltype": "monetaryItemType" }, "pyxs_DeferredTaxAssetsCapitalizedResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development.", "label": "Section 174 R&D Capitalization" } } }, "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "pyxs_DerivativeWarrantLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents derivative warrant liabilities.", "label": "Derivative Warrant Liabilities [Member]" } } }, "localname": "DerivativeWarrantLiabilitiesMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "pyxs_EffectOfRetroactiveApplicationOfRecapitalizationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents effect of retroactive application of recapitalization.", "label": "Effect of Retroactive Application of Recapitalization [Member]" } } }, "localname": "EffectOfRetroactiveApplicationOfRecapitalizationMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "domainItemType" }, "pyxs_EmergingGrowthCompanyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for emerging growth company.", "label": "Emerging Growth Company [Policy Text Block]" } } }, "localname": "EmergingGrowthCompanyPolicyTextBlock", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "pyxs_EquityStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Equity Stock Purchase Plan.", "label": "Equity Stock Purchase Plan [Member]" } } }, "localname": "EquityStockPurchasePlanMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-schedule-of-valuation-assumptions-of-stock-options-details" ], "xbrltype": "domainItemType" }, "pyxs_ExpenseFromVestingOfRestrictedStockAwards": { "auth_ref": [], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense from vesting of restricted stock awards.", "label": "Expense from restricted stock units" } } }, "localname": "ExpenseFromVestingOfRestrictedStockAwards", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "pyxs_ExtensionAndWorkingCapitalNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents extension and working capital notes.", "label": "Extension and Working Capital Notes [Member]" } } }, "localname": "ExtensionAndWorkingCapitalNotesMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-3-merger", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details" ], "xbrltype": "domainItemType" }, "pyxs_FinancingCostsInAccountsPayableAndOtherAccruedLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncash amount of financing costs included in accounts payable and other accrued liabilities.", "label": "Financing costs in accounts payable and other accrued liabilities" } } }, "localname": "FinancingCostsInAccountsPayableAndOtherAccruedLiabilities", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "pyxs_GrossProceedsFromIssuanceOfShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gross amount proceeds from issuance of shares.", "label": "pyxs_GrossProceedsFromIssuanceOfShares", "terseLabel": "Gross Proceeds from Issuance of Shares" } } }, "localname": "GrossProceedsFromIssuanceOfShares", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "pyxs_IncentiveStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Incentive Stock Option.", "label": "Incentive Stock Option [Member]" } } }, "localname": "IncentiveStockOptionMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "domainItemType" }, "pyxs_IncreaseDecreaseFairValueOfLiabilityForCommonStockToBeIssued": { "auth_ref": [], "calculation": { "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of changes in fair value of liability for common stock shares to be issued.", "label": "Change in fair value of liability for common stock to be issued", "terseLabel": "Increase (Decrease) Fair Value of Liability for Common Stock to be Issued" } } }, "localname": "IncreaseDecreaseFairValueOfLiabilityForCommonStockToBeIssued", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "pyxs_LaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents laboratory equipment.", "label": "Laboratory Equipment [Member]" } } }, "localname": "LaboratoryEquipmentMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies2BD6C28F-50E7-4037-A60B-045979707453", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-10-q-", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-10-q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-details" ], "xbrltype": "domainItemType" }, "pyxs_LegacyApexigenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Legacy Apexigen.", "label": "Legacy Apexigen [Member]" } } }, "localname": "LegacyApexigenMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-3-merger", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details" ], "xbrltype": "domainItemType" }, "pyxs_LincolnParkCapitalFundMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Lincoln Park Capital Fund.", "label": "Lincoln Park Capital Fund [Member]" } } }, "localname": "LincolnParkCapitalFundMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "pyxs_LincolnParkPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Lincoln Park Purchase Agreement.", "label": "Lincoln Park Purchase Agreement [Member]" } } }, "localname": "LincolnParkPurchaseAgreementMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "pyxs_MajorVendorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents major vendor.", "label": "Major Vendor [Member]" } } }, "localname": "MajorVendorMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies2BD6C28F-50E7-4037-A60B-045979707453" ], "xbrltype": "domainItemType" }, "pyxs_MajorVendorPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to major vendor.", "label": "Major Vendor [Policy Text Block]" } } }, "localname": "MajorVendorPolicyTextBlock", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "pyxs_MaximumAmountOfPurchaseOfCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents maximum amount of purchase of common stock.", "label": "pyxs_MaximumAmountOfPurchaseOfCommonStock", "terseLabel": "Maximum Amount of Purchase of Common Stock" } } }, "localname": "MaximumAmountOfPurchaseOfCommonStock", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "pyxs_MonthlyRent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents amount fo monthly rent.", "label": "pyxs_MonthlyRent", "terseLabel": "Monthly Rent" } } }, "localname": "MonthlyRent", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "pyxs_NasdaqCapitalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Nasdaq Capital.", "label": "Nasdaq Capital [Member]" } } }, "localname": "NasdaqCapitalMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "pyxs_NetProceedsFromBusinessCombinationAndPrivateOffering": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net amount of cash inflow from business combination and private offering.", "label": "Net proceeds from merger and private offering for the year ended December 31, 2022" } } }, "localname": "NetProceedsFromBusinessCombinationAndPrivateOffering", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details" ], "xbrltype": "monetaryItemType" }, "pyxs_NonExecutiveBoardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Non Executive Board.", "label": "Non Executive Board [Member]" } } }, "localname": "NonExecutiveBoardMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "domainItemType" }, "pyxs_NonstatutoryStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Nonstatutory Stock Option.", "label": "Nonstatutory Stock Option [Member]" } } }, "localname": "NonstatutoryStockOptionMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "domainItemType" }, "pyxs_NoteToFinancialStatementDetailsTextual": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "localname": "NoteToFinancialStatementDetailsTextual", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_NotesToFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "localname": "NotesToFinancialStatementsAbstract", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_NumberOfConsecutiveTradingDaysForDeterminingSharePriceTriggeringWarrantRedemption": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Duration of number of consecutive trading days to determine share price triggering warrant redemption.", "label": "pyxs_NumberOfConsecutiveTradingDaysForDeterminingSharePriceTriggeringWarrantRedemption", "terseLabel": "Number of Consecutive Trading Days for Determining Share Price Triggering Warrant Redemption (Day)" } } }, "localname": "NumberOfConsecutiveTradingDaysForDeterminingSharePriceTriggeringWarrantRedemption", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants-details-textual" ], "xbrltype": "durationItemType" }, "pyxs_NumberOfDaysCommencesForSharePurchaseAfterTheClosingAndTerminatingOnTheFiveyearAnniversary": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents number of days commences for share purchase after the closing and terminating on the five year anniversary.", "label": "pyxs_NumberOfDaysCommencesForSharePurchaseAfterTheClosingAndTerminatingOnTheFiveyearAnniversary", "terseLabel": "Number of Days Commences for Share Purchase After the Closing and Terminating on The Five-year Anniversary (Day)" } } }, "localname": "NumberOfDaysCommencesForSharePurchaseAfterTheClosingAndTerminatingOnTheFiveyearAnniversary", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textualB5161F24-A199-4D9A-9D11-680B80832079" ], "xbrltype": "durationItemType" }, "pyxs_NumberOfTradingDaysForDeterminingSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of trading days used to determine share price.", "label": "pyxs_NumberOfTradingDaysForDeterminingSharePrice", "terseLabel": "Number of Trading Days for Determining Share Price (Day)" } } }, "localname": "NumberOfTradingDaysForDeterminingSharePrice", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual" ], "xbrltype": "durationItemType" }, "pyxs_OperatingLossCarryforwardsNotSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforwards that are not subject to expiration dates.", "label": "pyxs_OperatingLossCarryforwardsNotSubjectToExpiration", "terseLabel": "Operating Loss Carryforwards Not Subject to Expiration" } } }, "localname": "OperatingLossCarryforwardsNotSubjectToExpiration", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "pyxs_OperatingLossCarryforwardsSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforwards that are subject to expiration.", "label": "pyxs_OperatingLossCarryforwardsSubjectToExpiration", "terseLabel": "Operating Loss Carryforwards Subject to Expiration" } } }, "localname": "OperatingLossCarryforwardsSubjectToExpiration", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "pyxs_OrphanDrugTaxCreditCarryForwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Orphan Drug Tax Credit Carry Forward.", "label": "Orphan Drug Tax Credit Carry Forward [Member]" } } }, "localname": "OrphanDrugTaxCreditCarryForwardMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "pyxs_OtherPrepaidExpensesAndCurrentAssets": { "auth_ref": [], "calculation": { "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-prepaid-expenses-and-other-current-assets-details": { "order": 0.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other prepaid expenses and current assets as of balance sheet date.", "label": "Other prepaid expenses and current assets" } } }, "localname": "OtherPrepaidExpensesAndCurrentAssets", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-prepaid-expenses-and-other-current-assets-details" ], "xbrltype": "monetaryItemType" }, "pyxs_OtherPrepaidExpensesAndCurrentAssetsIncludingDeferredFinancingCosts": { "auth_ref": [], "calculation": { "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-prepaid-expenses-and-other-current-assets-10q-details": { "order": 0.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other prepaid expenses and current assets including deferred financing costs.", "label": "pyxs_OtherPrepaidExpensesAndCurrentAssetsIncludingDeferredFinancingCosts", "terseLabel": "Other prepaid expenses and current assets" } } }, "localname": "OtherPrepaidExpensesAndCurrentAssetsIncludingDeferredFinancingCosts", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-prepaid-expenses-and-other-current-assets-10q-details" ], "xbrltype": "monetaryItemType" }, "pyxs_PIPEInvestmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents PIPE investment.", "label": "P I P E Investment [Member]" } } }, "localname": "PIPEInvestmentMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textualB5161F24-A199-4D9A-9D11-680B80832079", "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-businessA333C5D9-19D0-4567-932F-9815DE5E9A16", "http://pyxisoncology.com/20230331/role/statement-note-3-merger", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants-details-textual" ], "xbrltype": "domainItemType" }, "pyxs_PercentageOfExercisePriceWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price as percentage of exercise price of warrants.", "label": "pyxs_PercentageOfExercisePriceWarrants", "terseLabel": "Percentage of Exercise Price, Warrants" } } }, "localname": "PercentageOfExercisePriceWarrants", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual" ], "xbrltype": "percentItemType" }, "pyxs_PreferredStockWarrantLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents preferred stock warrant liability.", "label": "Preferred Stock Warrant Liability [Member]" } } }, "localname": "PreferredStockWarrantLiabilityMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "pyxs_PrepaidClinicalDevelopmentExpenses": { "auth_ref": [], "calculation": { "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-prepaid-expenses-and-other-current-assets-10q-details": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-prepaid-expenses-and-other-current-assets-details": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of prepaid clinical development expense as of balance sheet date.", "label": "Prepaid clinical development expenses" } } }, "localname": "PrepaidClinicalDevelopmentExpenses", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-prepaid-expenses-and-other-current-assets-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-prepaid-expenses-and-other-current-assets-details" ], "xbrltype": "monetaryItemType" }, "pyxs_PrivateOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents private offering.", "label": "Private Offering [Member]" } } }, "localname": "PrivateOfferingMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details" ], "xbrltype": "domainItemType" }, "pyxs_PrivatePlacementWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents private placement warrants.", "label": "Private Placement Warrants [Member]" } } }, "localname": "PrivatePlacementWarrantsMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants-details-textual" ], "xbrltype": "domainItemType" }, "pyxs_ProceedsFromBusinessCombinationAndPrivateOffering": { "auth_ref": [], "calculation": { "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from business combination and private offering.", "label": "Proceeds from merger and private offering", "terseLabel": "Proceeds From Business Combination and Private Offering", "totalLabel": "Proceeds from merger and private offering for the year ended December 31, 2022" } } }, "localname": "ProceedsFromBusinessCombinationAndPrivateOffering", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details" ], "xbrltype": "monetaryItemType" }, "pyxs_PublicWarrants2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Public Warrants 2.", "label": "Public Warrants 2 [Member]" } } }, "localname": "PublicWarrants2Member", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-details-textual" ], "xbrltype": "domainItemType" }, "pyxs_PublicWarrants3Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents public warrant 3.", "label": "Public Warrants 3 [Member]" } } }, "localname": "PublicWarrants3Member", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-details-textual" ], "xbrltype": "domainItemType" }, "pyxs_PublicWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents public warrants.", "label": "Public Warrants [Member]" } } }, "localname": "PublicWarrantsMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-measurement-inputs-and-valuation-techniques-of-warrants-details", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants-details-textual" ], "xbrltype": "domainItemType" }, "pyxs_PurchaseShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents purchase shares.", "label": "Purchase Share [Member]" } } }, "localname": "PurchaseShareMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "pyxs_RangeOfExercisePriceOnePointTwoSevenToTwoPointSixFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Range Of Exercise Price One Point Two Seven To Two Point Six Five.", "label": "Range Of Exercise Price One Point Two Seven To Two Point Six Five [Member]" } } }, "localname": "RangeOfExercisePriceOnePointTwoSevenToTwoPointSixFiveMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-exercise-price-range-of-options-details" ], "xbrltype": "domainItemType" }, "pyxs_RangeOfExercisePriceSixPointFiveFourToSevenPointSixTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Range Of Exercise Price Six Point Five Four To Seven Point Six Two.", "label": "Range Of Exercise Price Six Point Five Four To Seven Point Six Two [Member]" } } }, "localname": "RangeOfExercisePriceSixPointFiveFourToSevenPointSixTwoMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-exercise-price-range-of-options-details" ], "xbrltype": "domainItemType" }, "pyxs_RangeOfExercisePriceThreePointZeroThreeToFourPointSevenNineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Range Of Exercise Price Three Point Zero Three To Four Point Seven Nine.", "label": "Range Of Exercise Price Three Point Zero Three To Four Point Seven Nine [Member]" } } }, "localname": "RangeOfExercisePriceThreePointZeroThreeToFourPointSevenNineMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-exercise-price-range-of-options-details" ], "xbrltype": "domainItemType" }, "pyxs_RecapitalizationAppliedToConvertiblePreferredStockOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares recapitalization applied to convertible preferred stock outstanding.", "label": "Recapitalization applied to Convertible Preferred Stock outstanding at December 31, 2020 (in shares)" } } }, "localname": "RecapitalizationAppliedToConvertiblePreferredStockOutstanding", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details" ], "xbrltype": "sharesItemType" }, "pyxs_RecapitalizationAppliedToConvertiblePreferredStockOutstandingEffectedForExchangeRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares effected for exchange ratio under recapitalization applied to convertible preferred stock outstanding.", "label": "pyxs_RecapitalizationAppliedToConvertiblePreferredStockOutstandingEffectedForExchangeRatio", "terseLabel": "Recapitalization applied to Convertible Preferred Stock outstanding at December 31, 2020 (in shares)" } } }, "localname": "RecapitalizationAppliedToConvertiblePreferredStockOutstandingEffectedForExchangeRatio", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details" ], "xbrltype": "sharesItemType" }, "pyxs_ReclassificationOfWarrant": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of reclassification of warrants.", "label": "Reclassification of warrant" } } }, "localname": "ReclassificationOfWarrant", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "pyxs_RedemptionOfCommonShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares redemption.", "label": "pyxs_RedemptionOfCommonShares", "negatedLabel": "Less: redemption of BCAC shares (in shares)" } } }, "localname": "RedemptionOfCommonShares", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details" ], "xbrltype": "sharesItemType" }, "pyxs_ReverseStockSplitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The conversion of a reverse stock split where there is a reduction in the shares outstanding.", "label": "Reverse Stock Split [Member]" } } }, "localname": "ReverseStockSplitMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "pyxs_ScheduleOfConvertiblePreferredStockTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of convertible preferred stock.", "label": "Schedule of Convertible Preferred Stock [Table Text Block]" } } }, "localname": "ScheduleOfConvertiblePreferredStockTableTextBlock", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-tables", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-tables" ], "xbrltype": "textBlockItemType" }, "pyxs_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of prepaid expenses and other current assets.", "label": "Schedule of Prepaid Expenses and Other Current Assets [Table Text Block]" } } }, "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-10-q-tables", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-tables" ], "xbrltype": "textBlockItemType" }, "pyxs_SecuritiesPurchaseAgreementWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Securities Purchase Agreement Warrant.", "label": "Securities Purchase Agreement Warrant [Member]" } } }, "localname": "SecuritiesPurchaseAgreementWarrantMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events", "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "pyxs_SeriesA1PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Series A-1 preferred stock.", "label": "Series A-1 Preferred Stock [Member]" } } }, "localname": "SeriesA1PreferredStockMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-summary-of-convertible-preferred-stock-details", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-summary-of-convertible-preferred-stock-details" ], "xbrltype": "domainItemType" }, "pyxs_SeriesA2PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Series A-2 preferred stock.", "label": "Series A-2 Preferred Stock [Member]" } } }, "localname": "SeriesA2PreferredStockMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-summary-of-convertible-preferred-stock-details", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-summary-of-convertible-preferred-stock-details" ], "xbrltype": "domainItemType" }, "pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "<Maximum employee subscription amount under share-based compensation arrangement.", "label": "pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award, Maximum Employee Subscription Amount" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "monetaryItemType" }, "pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAwardsAvailableToGrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Awards available for options cancelled under share based compensation.", "label": "Options Cancelled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledAwardsAvailableToGrant", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details" ], "xbrltype": "sharesItemType" }, "pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedAwardsAvailableToGrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares available for grant for options exercised under sharebased compensation.", "label": "Options Exercised (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedAwardsAvailableToGrant", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details" ], "xbrltype": "sharesItemType" }, "pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedAwardsAvailableToGrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares available for grant for options granted under sharebased compensation.", "label": "Options Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedAwardsAvailableToGrant", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details" ], "xbrltype": "sharesItemType" }, "pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAuthorizedAwardsAvailableToGrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of awards available for grant for shares authorized under share based compensation.", "label": "Shares authorized added to 2022 Plan (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAuthorizedAwardsAvailableToGrant", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details" ], "xbrltype": "sharesItemType" }, "pyxs_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNotReturnToPlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares not return to plan under share based compensation.", "label": "Shares not returned to plan (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNotReturnToPlan", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details" ], "xbrltype": "sharesItemType" }, "pyxs_ShareBasedCompensationArrangementByShareBasedPaymentRestrictedStockAwardsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Awards available for sale for restricted stock awards granted", "label": "pyxs_ShareBasedCompensationArrangementByShareBasedPaymentRestrictedStockAwardsGranted", "negatedLabel": "Restricted stock awards granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentRestrictedStockAwardsGranted", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details" ], "xbrltype": "sharesItemType" }, "pyxs_ShareBasedCompensationArrangementByShareBasedPaymentRestrictedStockAwardsVested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares available for restricted stock vested.", "label": "Restricted stock awards vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentRestrictedStockAwardsVested", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details" ], "xbrltype": "sharesItemType" }, "pyxs_ShareBasedCompensationArrangementByShareBasedPaymentRestrictedStockUnitsForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Awards available for restricted stock units forfeited.", "label": "Restricted stock units forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentRestrictedStockUnitsForfeited", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details" ], "xbrltype": "sharesItemType" }, "pyxs_ShareBasedCompensationArrangementNumberOfOptionsForWhichRepricingApprovedForVariousEmployees": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options for which repricing approved for various employees under share-based compensation.", "label": "pyxs_ShareBasedCompensationArrangementNumberOfOptionsForWhichRepricingApprovedForVariousEmployees", "terseLabel": "Share Based Compensation Arrangement, Number of Options for Which Repricing Approved for Various Employees (in shares)" } } }, "localname": "ShareBasedCompensationArrangementNumberOfOptionsForWhichRepricingApprovedForVariousEmployees", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "sharesItemType" }, "pyxs_SharesAvailableForEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents shares available for Employee Stock Purchase Plan.", "label": "Shares Available for Employee Stock Purchase Plan [Member]" } } }, "localname": "SharesAvailableForEmployeeStockPurchasePlanMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-summary-of-common-stock-reserved-for-issuance-details", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-summary-of-common-stock-reserved-for-issuance-details" ], "xbrltype": "domainItemType" }, "pyxs_StockIssuedDuringPeriodSharesBusinessCombinationAndPrivateOfferingFinancingNet": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of business combination and private offering financing.", "label": "Merger and private offering, net of transaction costs of $9,232 (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesBusinessCombinationAndPrivateOfferingFinancingNet", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "sharesItemType" }, "pyxs_StockIssuedDuringPeriodSharesNonoptionEquityInstrumentsExercisedEffectedForExchangeRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares effected for exchange ratio for stock issued during period as a result of exercise of non-option equity instruments.", "label": "pyxs_StockIssuedDuringPeriodSharesNonoptionEquityInstrumentsExercisedEffectedForExchangeRatio", "terseLabel": "Exercise of common stock restricted awards - 2022 (pre-Closing) (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNonoptionEquityInstrumentsExercisedEffectedForExchangeRatio", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details" ], "xbrltype": "sharesItemType" }, "pyxs_StockIssuedDuringPeriodSharesStockOptionsExercisedEffectedForExchangeRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares effected for exchange ratio for stock issued during period as a result of option exercises.", "label": "pyxs_StockIssuedDuringPeriodSharesStockOptionsExercisedEffectedForExchangeRatio", "terseLabel": "Exercise of common stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercisedEffectedForExchangeRatio", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details" ], "xbrltype": "sharesItemType" }, "pyxs_StockIssuedDuringPeriodSharesWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of share warrants exercised during the current period.", "label": "Exercise of Legacy Apexigen common stock warrant (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesWarrantsExercised", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details" ], "xbrltype": "sharesItemType" }, "pyxs_StockIssuedDuringPeriodValueBusinessCombinationAndPrivateOfferingFinancingNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of business combination and private offering financing.", "label": "Merger and private offering, net of transaction costs of $9,232" } } }, "localname": "StockIssuedDuringPeriodValueBusinessCombinationAndPrivateOfferingFinancingNet", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "pyxs_StockIssuedDuringPeriodValuePreferredStockWarrantReclassification": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued during period as a result of preferred stock warrants reclassification.", "label": "Reclassification of preferred stock warrant" } } }, "localname": "StockIssuedDuringPeriodValuePreferredStockWarrantReclassification", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "pyxs_StockIssuedDuringPeriodValueWarrantsExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of warrants.", "label": "Exercise of common stock warrant" } } }, "localname": "StockIssuedDuringPeriodValueWarrantsExercised", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "pyxs_StockOptionsAvailableForFutureGrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents stock options available for future grants.", "label": "Stock Options Available for Future Grants [Member]" } } }, "localname": "StockOptionsAvailableForFutureGrantsMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-summary-of-common-stock-reserved-for-issuance-details", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-summary-of-common-stock-reserved-for-issuance-details" ], "xbrltype": "domainItemType" }, "pyxs_StockOptionsIssuedAndOutstandingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents stock options issued and outstanding.", "label": "Stock Options Issued and Outstanding [Member]" } } }, "localname": "StockOptionsIssuedAndOutstandingMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-summary-of-common-stock-reserved-for-issuance-details", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-summary-of-common-stock-reserved-for-issuance-details" ], "xbrltype": "domainItemType" }, "pyxs_TransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction costs.", "label": "pyxs_TransactionCosts", "terseLabel": "Transaction Costs" } } }, "localname": "TransactionCosts", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "pyxs_TransactionCostsInAccountsPayableAndAccruedLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncash amount of transaction costs included in accounts payable and accrued liabilities.", "label": "Transaction costs in accounts payable and accrued liabilities at period end" } } }, "localname": "TransactionCostsInAccountsPayableAndAccruedLiabilities", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "pyxs_TransactionCostsPaidInCash": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction costs paid in cash.", "label": "pyxs_TransactionCostsPaidInCash", "terseLabel": "Transaction Costs Paid in Cash" } } }, "localname": "TransactionCostsPaidInCash", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "pyxs_TransactionCostsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for transaction costs.", "label": "Transaction Costs [Policy Text Block]" } } }, "localname": "TransactionCostsPolicyTextBlock", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "pyxs_TwoThousandAndTenEquityIncentivePlanOrTwoThousandAndTwentyEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Two Thousand and Ten Equity Incentive Plan or Two Thousand and Twenty Equity Incentive Plan.", "label": "Two Thousand and Ten Equity Incentive Plan or Two Thousand and Twenty Equity Incentive Plan [Member]" } } }, "localname": "TwoThousandAndTenEquityIncentivePlanOrTwoThousandAndTwentyEquityIncentivePlanMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "domainItemType" }, "pyxs_TwoThousandTwentyTwoEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Two Thousand Twenty Two Equity Incentive Plan.", "label": "Two Thousand Twenty Two Equity Incentive Plan [Member]" } } }, "localname": "TwoThousandTwentyTwoEquityIncentivePlanMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "domainItemType" }, "pyxs_TwoThousandTwentyTwoPIPEMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Two Thousand Twenty Two PIPE.", "label": "Two Thousand Twenty Two P I P E [Member]" } } }, "localname": "TwoThousandTwentyTwoPIPEMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "pyxs_TwoVendorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents two vendors.", "label": "Two Vendors [Member]" } } }, "localname": "TwoVendorsMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "pyxs_UnauditedInterimFinancialStatementsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for unaudited interim financial statements.", "label": "Unaudited Interim Financial Statements [Policy Text Block]" } } }, "localname": "UnauditedInterimFinancialStatementsPolicyTextBlock", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "pyxs_UnitsGrantedOctober2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Relating to units granted October 2022.", "label": "Units Granted October 2022 [Member]" } } }, "localname": "UnitsGrantedOctober2022Member", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "domainItemType" }, "pyxs_WarrantRedemptionConditionMinimumSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum share price under warrant redemption conditions.", "label": "pyxs_WarrantRedemptionConditionMinimumSharePrice", "terseLabel": "Warrant Redemption Condition, Minimum Share Price (in dollars per share)" } } }, "localname": "WarrantRedemptionConditionMinimumSharePrice", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants-details-textual" ], "xbrltype": "perShareItemType" }, "pyxs_WarrantWithEngagementAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents warrants with engagement agreement.", "label": "Warrant With Engagement Agreement [Member]" } } }, "localname": "WarrantWithEngagementAgreementMember", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events", "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "pyxs_WarrantsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for warrants.", "label": "Warrants [Text Block]" } } }, "localname": "WarrantsTextBlock", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants" ], "xbrltype": "textBlockItemType" }, "pyxs_WorkforceReductionPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents reducing workforce as a percentage.", "label": "pyxs_WorkforceReductionPercent", "terseLabel": "Workforce Reduction, Percent" } } }, "localname": "WorkforceReductionPercent", "nsuri": "http://pyxisoncology.com/20230331", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textual" ], "xbrltype": "percentItemType" }, "pyxs_statement-statement-note-11-income-taxes-reconciliation-of-effective-income-tax-rate-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Income Taxes - Reconciliation of Effective Income Tax Rate (Details)" } } }, "localname": "statement-statement-note-11-income-taxes-reconciliation-of-effective-income-tax-rate-details", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-11-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)" } } }, "localname": "statement-statement-note-11-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-11-income-taxes-schedule-of-unrecognized-tax-benefits-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)" } } }, "localname": "statement-statement-note-11-income-taxes-schedule-of-unrecognized-tax-benefits-details", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-11-income-taxes-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Income Taxes" } } }, "localname": "statement-statement-note-11-income-taxes-tables", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-11-net-loss-per-share-antidilutive-securities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Net Loss Per Share - Antidilutive Securities (Details)" } } }, "localname": "statement-statement-note-11-net-loss-per-share-antidilutive-securities-details", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-11-net-loss-per-share-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 11 - Net Loss Per Share" } } }, "localname": "statement-statement-note-11-net-loss-per-share-tables", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-12-net-loss-per-share-antidilutive-securities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 12 - Net Loss Per Share - Antidilutive Securities (Details)" } } }, "localname": "statement-statement-note-12-net-loss-per-share-antidilutive-securities-details", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-12-net-loss-per-share-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 12 - Net Loss Per Share" } } }, "localname": "statement-statement-note-12-net-loss-per-share-tables", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-3-merger-10q-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Merger (10Q)" } } }, "localname": "statement-statement-note-3-merger-10q-tables", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Merger - Schedule of Elements of Business Combination (10Q) (Details)" } } }, "localname": "statement-statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-3-merger-schedule-of-elements-of-business-combination-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Merger - Schedule of Elements of Business Combination (Details)" } } }, "localname": "statement-statement-note-3-merger-schedule-of-elements-of-business-combination-details", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-3-merger-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Merger" } } }, "localname": "statement-statement-note-3-merger-tables", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-4-fair-value-measurement-10q-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Fair Value Measurement (10Q)" } } }, "localname": "statement-statement-note-4-fair-value-measurement-10q-tables", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-10q-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Fair Value Measurement - Estimated Fair Value of Marketable Securities and Gross Unrealized Holding Gains and Losses (10Q) (Details)" } } }, "localname": "statement-statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-10q-details", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Fair Value Measurement - Estimated Fair Value of Marketable Securities and Gross Unrealized Holding Gains and Losses (Details)" } } }, "localname": "statement-statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-details", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-10q-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Fair Value Measurement - Financial Instruments on Recurring Basis (10Q) (Details)" } } }, "localname": "statement-statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-10q-details", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Fair Value Measurement - Financial Instruments on Recurring Basis (Details)" } } }, "localname": "statement-statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-details", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-4-fair-value-measurement-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Fair Value Measurement" } } }, "localname": "statement-statement-note-4-fair-value-measurement-tables", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-5-balance-sheet-components-10-q-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Balance Sheet Components (10 Q)" } } }, "localname": "statement-statement-note-5-balance-sheet-components-10-q-tables", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-5-balance-sheet-components-summary-of-accrued-liabilities-10q-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Balance Sheet Components - Summary of Accrued Liabilities (10Q) (Details)" } } }, "localname": "statement-statement-note-5-balance-sheet-components-summary-of-accrued-liabilities-10q-details", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-5-balance-sheet-components-summary-of-accrued-liabilities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Balance Sheet Components - Summary of Accrued Liabilities (Details)" } } }, "localname": "statement-statement-note-5-balance-sheet-components-summary-of-accrued-liabilities-details", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-5-balance-sheet-components-summary-of-prepaid-expenses-and-other-current-assets-10q-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Balance Sheet Components - Summary of Prepaid Expenses and Other Current Assets (10Q) (Details)" } } }, "localname": "statement-statement-note-5-balance-sheet-components-summary-of-prepaid-expenses-and-other-current-assets-10q-details", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-5-balance-sheet-components-summary-of-prepaid-expenses-and-other-current-assets-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Balance Sheet Components - Summary of Prepaid Expenses and Other Current Assets (Details)" } } }, "localname": "statement-statement-note-5-balance-sheet-components-summary-of-prepaid-expenses-and-other-current-assets-details", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-10q-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Balance Sheet Components - Summary of Property, Plant and Equipment (10Q) (Details)" } } }, "localname": "statement-statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-10q-details", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Balance Sheet Components - Summary of Property, Plant and Equipment (Details)" } } }, "localname": "statement-statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-details", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-5-balance-sheet-components-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Balance Sheet Components" } } }, "localname": "statement-statement-note-5-balance-sheet-components-tables", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-6-lease-maturity-of-operating-lease-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Lease - Maturity of Operating Lease (Details)" } } }, "localname": "statement-statement-note-6-lease-maturity-of-operating-lease-details", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-6-lease-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Lease" } } }, "localname": "statement-statement-note-6-lease-tables", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-6-stockholders-equity-summary-of-common-stock-reserved-for-issuance-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Stockholder's Equity - Summary of Common Stock Reserved for Issuance (Details)" } } }, "localname": "statement-statement-note-6-stockholders-equity-summary-of-common-stock-reserved-for-issuance-details", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-6-stockholders-equity-summary-of-convertible-preferred-stock-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Stockholder's Equity - Summary of Convertible Preferred Stock (Details)" } } }, "localname": "statement-statement-note-6-stockholders-equity-summary-of-convertible-preferred-stock-details", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-6-stockholders-equity-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Stockholder's Equity" } } }, "localname": "statement-statement-note-6-stockholders-equity-tables", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-7-public-and-private-warrants-measurement-inputs-and-valuation-techniques-of-warrants-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Public and Private Warrants - Measurement Inputs and Valuation Techniques of Warrants (Details)" } } }, "localname": "statement-statement-note-7-public-and-private-warrants-measurement-inputs-and-valuation-techniques-of-warrants-details", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-7-public-and-private-warrants-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Public and Private Warrants" } } }, "localname": "statement-statement-note-7-public-and-private-warrants-tables", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-7-stockholders-equity-summary-of-common-stock-reserved-for-issuance-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Stockholder's Equity - Summary of Common Stock Reserved for Issuance (Details)" } } }, "localname": "statement-statement-note-7-stockholders-equity-summary-of-common-stock-reserved-for-issuance-details", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-7-stockholders-equity-summary-of-convertible-preferred-stock-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Stockholder's Equity - Summary of Convertible Preferred Stock (Details)" } } }, "localname": "statement-statement-note-7-stockholders-equity-summary-of-convertible-preferred-stock-details", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-7-stockholders-equity-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Stockholder's Equity" } } }, "localname": "statement-statement-note-7-stockholders-equity-tables", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-8-equity-plans-and-related-equity-activities-stockbased-compensation-expense-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Equity Plans and Related Equity Activities - Stock-based Compensation Expense (Details)" } } }, "localname": "statement-statement-note-8-equity-plans-and-related-equity-activities-stockbased-compensation-expense-details", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-8-equity-plans-and-related-equity-activities-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Equity Plans and Related Equity Activities" } } }, "localname": "statement-statement-note-8-equity-plans-and-related-equity-activities-tables", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-9-equity-plans-and-related-equity-activities-exercise-price-range-of-options-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Equity Plans and Related Equity Activities - Exercise Price Range of Options (Details)" } } }, "localname": "statement-statement-note-9-equity-plans-and-related-equity-activities-exercise-price-range-of-options-details", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-9-equity-plans-and-related-equity-activities-schedule-of-valuation-assumptions-of-stock-options-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Equity Plans and Related Equity Activities - Schedule of Valuation Assumptions of Stock Options (Details)" } } }, "localname": "statement-statement-note-9-equity-plans-and-related-equity-activities-schedule-of-valuation-assumptions-of-stock-options-details", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-9-equity-plans-and-related-equity-activities-stockbased-compensation-expense-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Equity Plans and Related Equity Activities - Stock-based Compensation Expense (Details)" } } }, "localname": "statement-statement-note-9-equity-plans-and-related-equity-activities-stockbased-compensation-expense-details", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Equity Plans and Related Equity Activities - Summary of Activities Under the Plans (Details)" } } }, "localname": "statement-statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-note-9-equity-plans-and-related-equity-activities-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Equity Plans and Related Equity Activities" } } }, "localname": "statement-statement-note-9-equity-plans-and-related-equity-activities-tables", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "pyxs_statement-statement-significant-accounting-policies-policies": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "statement-statement-significant-accounting-policies-policies", "nsuri": "http://pyxisoncology.com/20230331", "xbrltype": "stringItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r193", "r194", "r311", "r329", "r498", "r712", "r714" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details" ], "xbrltype": "stringItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [ "r274", "r275", "r276" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r295", "r296", "r297", "r298", "r374", "r532", "r569", "r616", "r617", "r673", "r677", "r679", "r680", "r693", "r707", "r708", "r721", "r729", "r735", "r750", "r820", "r869", "r870", "r871", "r872", "r873", "r874" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-10-commitments-and-contingencies", "http://pyxisoncology.com/20230331/role/statement-note-10-commitments-and-contingencies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies2BD6C28F-50E7-4037-A60B-045979707453", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-commitments-and-contingencies", "http://pyxisoncology.com/20230331/role/statement-note-9-commitments-and-contingencies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-schedule-of-valuation-assumptions-of-stock-options-details" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r295", "r296", "r297", "r298", "r374", "r532", "r569", "r616", "r617", "r673", "r677", "r679", "r680", "r693", "r707", "r708", "r721", "r729", "r735", "r750", "r820", "r869", "r870", "r871", "r872", "r873", "r874" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies2BD6C28F-50E7-4037-A60B-045979707453", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-schedule-of-valuation-assumptions-of-stock-options-details" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r295", "r296", "r297", "r298", "r356", "r374", "r403", "r404", "r405", "r508", "r532", "r569", "r616", "r617", "r673", "r677", "r679", "r680", "r693", "r707", "r708", "r721", "r729", "r735", "r750", "r753", "r816", "r820", "r870", "r871", "r872", "r873", "r874" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-10-commitments-and-contingencies", "http://pyxisoncology.com/20230331/role/statement-note-10-commitments-and-contingencies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies2BD6C28F-50E7-4037-A60B-045979707453", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-commitments-and-contingencies", "http://pyxisoncology.com/20230331/role/statement-note-9-commitments-and-contingencies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-schedule-of-valuation-assumptions-of-stock-options-details" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r295", "r296", "r297", "r298", "r356", "r374", "r403", "r404", "r405", "r508", "r532", "r569", "r616", "r617", "r673", "r677", "r679", "r680", "r693", "r707", "r708", "r721", "r729", "r735", "r750", "r753", "r816", "r820", "r870", "r871", "r872", "r873", "r874" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-10-commitments-and-contingencies", "http://pyxisoncology.com/20230331/role/statement-note-10-commitments-and-contingencies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies2BD6C28F-50E7-4037-A60B-045979707453", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-commitments-and-contingencies", "http://pyxisoncology.com/20230331/role/statement-note-9-commitments-and-contingencies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-schedule-of-valuation-assumptions-of-stock-options-details" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r193", "r194", "r311", "r329", "r498", "r713", "r714" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r157", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r207", "r208", "r209", "r210", "r211", "r212", "r224", "r279", "r280", "r441", "r462", "r463", "r464", "r465", "r485", "r494", "r495", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r583" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r157", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r207", "r208", "r209", "r210", "r211", "r212", "r224", "r279", "r280", "r441", "r462", "r463", "r464", "r465", "r485", "r494", "r495", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r583" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "domainItemType" }, "srt_ScenarioPreviouslyReportedMember": { "auth_ref": [ "r157", "r197", "r199", "r200", "r201", "r202", "r203", "r211", "r224", "r441", "r462", "r463", "r464", "r485", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r583", "r766", "r768", "r769", "r770", "r798", "r813", "r814", "r857", "r863", "r864" ], "lang": { "en-us": { "role": { "label": "Previously Reported [Member]" } } }, "localname": "ScenarioPreviouslyReportedMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r274", "r275", "r276" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r802", "r865" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.", "label": "Accounts Payable and Accrued Liabilities [Member]" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies2BD6C28F-50E7-4037-A60B-045979707453" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r26", "r749" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-accrued-liabilities-10q-details": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-accrued-liabilities-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued liabilities", "totalLabel": "Total accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-accrued-liabilities-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-accrued-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r55", "r163", "r560" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-10q-details": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 }, "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-details": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "negatedLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r34", "r35", "r105", "r169", "r556", "r575", "r579" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.", "label": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r3", "r10", "r35", "r455", "r458", "r495", "r570", "r571", "r785", "r786", "r787", "r795", "r796", "r797" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r99", "r749", "r881" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r412", "r413", "r414", "r595", "r795", "r796", "r797", "r856", "r882" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r66", "r67", "r376" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r11", "r126" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Transaction costs" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited-parentheticals", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity-parentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r407", "r419" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Share-Based Payment Arrangement, Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-stockbased-compensation-expense-details", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-stockbased-compensation-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDeferredCharges": { "auth_ref": [ "r109" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of amortization of deferred charges applied against earnings during the period.", "label": "Amortization of deferred financing costs" } } }, "localname": "AmortizationOfDeferredCharges", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r108", "r323", "r483", "r790" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "us-gaap_AmortizationOfFinancingCosts", "terseLabel": "Amortization of Debt Issuance Costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r221" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-net-loss-per-share-antidilutive-securities-details", "http://pyxisoncology.com/20230331/role/statement-note-12-net-loss-per-share-antidilutive-securities-details" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-net-loss-per-share-antidilutive-securities-details", "http://pyxisoncology.com/20230331/role/statement-note-12-net-loss-per-share-antidilutive-securities-details" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-net-loss-per-share-antidilutive-securities-details", "http://pyxisoncology.com/20230331/role/statement-note-12-net-loss-per-share-antidilutive-securities-details" ], "xbrltype": "domainItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r730", "r805", "r806", "r807" ], "lang": { "en-us": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset-Backed Securities [Member]" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r137", "r165", "r191", "r228", "r237", "r239", "r277", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r450", "r452", "r474", "r553", "r638", "r749", "r761", "r818", "r819", "r867" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r159", "r170", "r191", "r277", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r450", "r452", "r474", "r749", "r818", "r819", "r867" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r84" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Financial assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsHeldInTrust": { "auth_ref": [ "r791" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations.", "label": "us-gaap_AssetsHeldInTrust", "terseLabel": "Asset, Held-in-Trust" } } }, "localname": "AssetsHeldInTrust", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textualB5161F24-A199-4D9A-9D11-680B80832079", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r247" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Unrealized gains, securities" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r248" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "negatedLabel": "Unrealized loss, securities" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r244", "r287", "r552" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "marketable securities, amortization cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r245", "r287", "r547", "r803" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Marketable Securities, fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848" ], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date [Axis]" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [ "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848" ], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted.", "label": "Award Date [Domain]" } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r378", "r379", "r380", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r402", "r403", "r404", "r405", "r406" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-schedule-of-valuation-assumptions-of-stock-options-details", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r448", "r733", "r734" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textualB5161F24-A199-4D9A-9D11-680B80832079", "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-businessA333C5D9-19D0-4567-932F-9815DE5E9A16", "http://pyxisoncology.com/20230331/role/statement-note-3-merger", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r71", "r72", "r448", "r733", "r734" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textualB5161F24-A199-4D9A-9D11-680B80832079", "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-businessA333C5D9-19D0-4567-932F-9815DE5E9A16", "http://pyxisoncology.com/20230331/role/statement-note-3-merger", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.", "label": "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "negatedLabel": "Less: transaction costs paid in 2022", "terseLabel": "Business Acquisition, Transaction Costs" } } }, "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textualB5161F24-A199-4D9A-9D11-680B80832079", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "us-gaap_BusinessAcquisitionSharePrice", "terseLabel": "Business Acquisition, Share Price (in dollars per share)" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r132", "r449" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-3-merger", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r73", "r74" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textualB5161F24-A199-4D9A-9D11-680B80832079", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r42", "r43", "r44" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Purchase of equipment included in accounts payable" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalUnitsAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.", "label": "us-gaap_CapitalUnitsAuthorized", "terseLabel": "Capital Units, Authorized (in shares)" } } }, "localname": "CapitalUnitsAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_CashAcquiredFromAcquisition": { "auth_ref": [ "r38" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details": { "order": 0.0, "parentTag": "pyxs_ProceedsFromBusinessCombinationAndPrivateOffering", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details": { "order": 1.0, "parentTag": "pyxs_ProceedsFromBusinessCombinationAndPrivateOffering", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).", "label": "Cash - BCAC's trust (net of redemption)" } } }, "localname": "CashAcquiredFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r40", "r161", "r710" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [ "r161" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textualB5161F24-A199-4D9A-9D11-680B80832079", "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-businessA333C5D9-19D0-4567-932F-9815DE5E9A16", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-details" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "fair value" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r784" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "us-gaap_CashCashEquivalentsAndShortTermInvestments", "terseLabel": "Cash, Cash Equivalents, and Short-Term Investments" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textualB5161F24-A199-4D9A-9D11-680B80832079" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r40", "r115", "r188" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r2", "r115" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net decrease in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r779", "r877" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "cash equivalents, amortized cost" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of non-cash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_CashMember": { "auth_ref": [ "r161" ], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.", "label": "Cash [Member]" } } }, "localname": "CashMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textualB5161F24-A199-4D9A-9D11-680B80832079", "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-businessA333C5D9-19D0-4567-932F-9815DE5E9A16", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-details" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r155", "r166", "r167", "r168", "r191", "r215", "r216", "r218", "r220", "r226", "r227", "r277", "r299", "r301", "r302", "r303", "r306", "r307", "r326", "r327", "r331", "r334", "r341", "r474", "r589", "r590", "r591", "r592", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r626", "r647", "r665", "r699", "r700", "r701", "r702", "r703", "r764", "r792", "r799" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-summary-of-common-stock-reserved-for-issuance-details", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-summary-of-convertible-preferred-stock-details", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-summary-of-common-stock-reserved-for-issuance-details", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-summary-of-convertible-preferred-stock-details" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events", "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-measurement-inputs-and-valuation-techniques-of-warrants-details", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events", "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-measurement-inputs-and-valuation-techniques-of-warrants-details", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textualB5161F24-A199-4D9A-9D11-680B80832079", "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "terseLabel": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textualB5161F24-A199-4D9A-9D11-680B80832079" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r342" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "us-gaap_ClassOfWarrantOrRightOutstanding", "terseLabel": "Class of Warrant or Right, Outstanding (in shares)" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r124", "r755", "r756", "r757", "r758" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": { "auth_ref": [ "r822", "r858" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.", "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]" } } }, "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-details" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r31", "r89", "r554", "r625" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitment and contingencies (Note 9)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r123", "r293", "r294", "r706", "r817" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-10-commitments-and-contingencies", "http://pyxisoncology.com/20230331/role/statement-note-9-commitments-and-contingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Shares Reserved for Future Issuance (in shares)", "terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-summary-of-common-stock-reserved-for-issuance-details", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-summary-of-common-stock-reserved-for-issuance-details", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r751", "r752", "r753", "r755", "r756", "r757", "r758", "r795", "r796", "r856", "r879", "r882" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r98" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)", "terseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets-parentheticals", "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r98", "r626" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized (in shares)", "terseLabel": "Common Stock, Shares Authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets-parentheticals", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r98" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r11", "r98", "r626", "r644", "r882", "r883" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets-parentheticals", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r98", "r555", "r749" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.0001 par value; 1,000,000,000 shares authorized as of March 31, 2023 (unaudited) and December 31, 2022; 24,652,546 and 22,646,015 shares issued and outstanding as of March 31, 2023 (unaudited) and December 31, 2022, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r36", "r177", "r179", "r185", "r549", "r565" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "us-gaap_ComprehensiveIncomeNetOfTax", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive Loss:" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r47", "r49", "r86", "r87", "r242", "r705" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies2BD6C28F-50E7-4037-A60B-045979707453" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r47", "r49", "r86", "r87", "r242", "r580", "r705" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies2BD6C28F-50E7-4037-A60B-045979707453" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r47", "r49", "r86", "r87", "r242", "r705", "r765" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies2BD6C28F-50E7-4037-A60B-045979707453" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r90", "r148" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r47", "r49", "r86", "r87", "r242" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "us-gaap_ConcentrationRiskPercentage1", "terseLabel": "Concentration Risk, Percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r47", "r49", "r86", "r87", "r242", "r705" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies2BD6C28F-50E7-4037-A60B-045979707453" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r75", "r715" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r344", "r345", "r354" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred revenue", "terseLabel": "Contract with Customer, Liability, Current" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r42", "r43", "r44" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "us-gaap_ConversionOfStockSharesConverted1", "terseLabel": "Conversion of Stock, Shares Converted (in shares)" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r730", "r732", "r878" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r24", "r93", "r94", "r138", "r140", "r196", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r484", "r724", "r725", "r726", "r727", "r728", "r793" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textualB5161F24-A199-4D9A-9D11-680B80832079", "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-businessA333C5D9-19D0-4567-932F-9815DE5E9A16", "http://pyxisoncology.com/20230331/role/statement-note-3-merger", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r30", "r196", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r484", "r724", "r725", "r726", "r727", "r728", "r793" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textualB5161F24-A199-4D9A-9D11-680B80832079", "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-businessA333C5D9-19D0-4567-932F-9815DE5E9A16", "http://pyxisoncology.com/20230331/role/statement-note-3-merger", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredChargesPolicyTextBlock": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.", "label": "Deferred Charges, Policy [Policy Text Block]" } } }, "localname": "DeferredChargesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredCosts": { "auth_ref": [ "r136", "r780" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.", "label": "Deferred financing costs, non-current" } } }, "localname": "DeferredCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsCurrent": { "auth_ref": [ "r783" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.", "label": "Deferred financing costs, current" } } }, "localname": "DeferredCostsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsCurrentAndNoncurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The carrying amount of deferred costs.", "label": "us-gaap_DeferredCostsCurrentAndNoncurrent", "terseLabel": "Deferred Costs" } } }, "localname": "DeferredCostsCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNoncurrentNet": { "auth_ref": [ "r88" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "us-gaap_DeferredFinanceCostsNoncurrentNet", "terseLabel": "Debt Issuance Costs, Noncurrent, Net" } } }, "localname": "DeferredFinanceCostsNoncurrentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r95", "r96", "r139", "r434" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "us-gaap_DeferredIncomeTaxLiabilities", "negatedTotalLabel": "Gross deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r435" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "us-gaap_DeferredTaxAssetsGross", "totalLabel": "Gross deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r853" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r70", "r854" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net operating loss carry forwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": { "auth_ref": [], "calculation": { "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.", "label": "Depreciation and amortization" } } }, "localname": "DeferredTaxAssetsPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r69", "r70", "r854" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Tax credits" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r70", "r854" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "terseLabel": "Stock-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther": { "auth_ref": [ "r70", "r854" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.", "label": "Other reserves and accruals" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r436" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "us-gaap_DeferredTaxAssetsValuationAllowance", "negatedLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "auth_ref": [ "r70", "r854" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.", "label": "us-gaap_DeferredTaxLiabilitiesLeasingArrangements", "negatedLabel": "Right-of-use assets" } } }, "localname": "DeferredTaxLiabilitiesLeasingArrangements", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r70", "r854" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment", "negatedLabel": "Depreciation and amortization" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r373" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "us-gaap_DefinedContributionPlanCostRecognized", "terseLabel": "Defined Contribution Plan, Cost" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-13-401k-plan-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage employer matches of the employee's percentage contribution matched.", "label": "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "terseLabel": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-13-401k-plan-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.", "label": "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "terseLabel": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent" } } }, "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-13-401k-plan-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r6", "r54" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-10-q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [ "r614", "r617", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r639", "r640", "r641", "r642", "r653", "r654", "r655", "r656", "r659", "r660", "r661", "r662", "r683", "r684", "r687", "r689", "r751", "r753" ], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-10q", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r79", "r80", "r81", "r82", "r614", "r617", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r639", "r640", "r641", "r642", "r653", "r654", "r655", "r656", "r659", "r660", "r661", "r662", "r683", "r684", "r687", "r689", "r714", "r751", "r753" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-10q", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r171", "r172", "r473", "r607", "r608", "r609", "r611", "r612", "r613", "r614", "r616", "r617", "r639", "r641", "r642", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r714", "r880" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "us-gaap_DerivativeLiabilities", "terseLabel": "Derivative Liability" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "auth_ref": [ "r171" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative warrant liabilities" } } }, "localname": "DerivativeLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r12", "r76", "r77", "r78", "r83", "r195" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r375", "r377", "r408", "r409", "r411", "r736" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business", "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-businessA333C5D9-19D0-4567-932F-9815DE5E9A16", "http://pyxisoncology.com/20230331/role/statement-note-10-commitments-and-contingencies", "http://pyxisoncology.com/20230331/role/statement-note-10-income-taxes", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes", "http://pyxisoncology.com/20230331/role/statement-note-11-net-loss-per-share", "http://pyxisoncology.com/20230331/role/statement-note-12-net-loss-per-share", "http://pyxisoncology.com/20230331/role/statement-note-12-subsequent-event", "http://pyxisoncology.com/20230331/role/statement-note-13-401k-plan", "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies2BD6C28F-50E7-4037-A60B-045979707453", "http://pyxisoncology.com/20230331/role/statement-note-3-merger", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-10q", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-10-q-", "http://pyxisoncology.com/20230331/role/statement-note-6-lease", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants", "http://pyxisoncology.com/20230331/role/statement-note-9-commitments-and-contingencies", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities" ], "xbrltype": "stringItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r186", "r202", "r203", "r205", "r206", "r208", "r214", "r215", "r218", "r219", "r220", "r224", "r464", "r465", "r550", "r566", "r717" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Net loss per share (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r45", "r46" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r213", "r221", "r222", "r223" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-net-loss-per-share", "http://pyxisoncology.com/20230331/role/statement-note-12-net-loss-per-share" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r427" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-reconciliation-of-effective-income-tax-rate-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "totalLabel": "Effective Income Tax Rate Reconciliation, Percent" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-reconciliation-of-effective-income-tax-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r192", "r427", "r444" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-reconciliation-of-effective-income-tax-rate-details": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Federal statutory income tax rate", "terseLabel": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-10-income-taxes-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-reconciliation-of-effective-income-tax-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r851", "r855" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-reconciliation-of-effective-income-tax-rate-details": { "order": 0.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "negatedLabel": "Change in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-reconciliation-of-effective-income-tax-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": { "auth_ref": [ "r851", "r855" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-reconciliation-of-effective-income-tax-rate-details": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Permanent differences" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-reconciliation-of-effective-income-tax-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r851", "r855" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-reconciliation-of-effective-income-tax-rate-details": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments", "negatedLabel": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-reconciliation-of-effective-income-tax-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther": { "auth_ref": [ "r851", "r855" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-reconciliation-of-effective-income-tax-rate-details": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.", "label": "Other credit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-reconciliation-of-effective-income-tax-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-accrued-liabilities-10q-details": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-accrued-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued personnel costs" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-accrued-liabilities-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-accrued-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r410" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r849" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r849" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-net-loss-per-share-antidilutive-securities-details", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-schedule-of-valuation-assumptions-of-stock-options-details" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r11", "r156", "r181", "r182", "r183", "r197", "r198", "r199", "r201", "r209", "r211", "r225", "r278", "r281", "r343", "r412", "r413", "r414", "r440", "r441", "r454", "r455", "r456", "r457", "r458", "r459", "r463", "r475", "r477", "r478", "r479", "r480", "r481", "r495", "r570", "r571", "r572", "r595", "r665" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "us-gaap_EquityMethodInvestmentOwnershipPercentage", "terseLabel": "Equity Method Investment, Ownership Percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r1", "r6" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "us-gaap_FairValueAdjustmentOfWarrants", "terseLabel": "Fair Value Adjustment of Warrants" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r22", "r84", "r85", "r135" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-10q-tables", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r84", "r85" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r316", "r358", "r359", "r360", "r361", "r362", "r363", "r468", "r505", "r506", "r507", "r725", "r726", "r730", "r731", "r732" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r85", "r134" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r467", "r468", "r470", "r471", "r472" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-10q" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r316", "r358", "r363", "r468", "r505", "r730", "r731", "r732" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r316", "r358", "r363", "r468", "r506", "r725", "r726", "r730", "r731", "r732" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r316", "r358", "r359", "r360", "r361", "r362", "r363", "r468", "r507", "r725", "r726", "r730", "r731", "r732" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r316", "r358", "r359", "r360", "r361", "r362", "r363", "r505", "r506", "r507", "r725", "r726", "r730", "r731", "r732" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r466", "r472" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r282", "r283", "r284", "r285", "r286", "r288", "r289", "r290", "r324", "r339", "r460", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r564", "r722", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r808", "r809", "r810", "r811" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-details" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.", "label": "Financial liability" } } }, "localname": "FinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies2BD6C28F-50E7-4037-A60B-045979707453", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r6" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "us-gaap_GainLossOnSaleOfPropertyPlantEquipment", "negatedLabel": "Gain on disposals", "terseLabel": "Gain (Loss) on Disposition of Property Plant Equipment" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-10-q-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r110", "r649" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative", "terseLabel": "General and Administrative Expense" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r107" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-stockbased-compensation-expense-details", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-stockbased-compensation-expense-details" ], "xbrltype": "domainItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r6", "r53", "r121" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse", "terseLabel": "Impairment, Long-Lived Asset, Held-for-Use" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r0", "r122" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r291", "r292", "r650" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-stockbased-compensation-expense-details", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-stockbased-compensation-expense-details" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r292", "r650" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-stockbased-compensation-expense-details", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-stockbased-compensation-expense-details" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r192", "r422", "r428", "r431", "r438", "r442", "r445", "r446", "r447", "r594" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-10-income-taxes", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r145", "r153", "r210", "r211", "r229", "r426", "r443", "r568" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "us-gaap_IncomeTaxExpenseBenefit", "terseLabel": "Income Tax Expense (Benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r180", "r424", "r425", "r431", "r432", "r437", "r439", "r588" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r5" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r5" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r533", "r789" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "us-gaap_IncreaseDecreaseInContractWithCustomerLiability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDerivativeLiabilities": { "auth_ref": [ "r789" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).", "label": "Change in fair value of derivative warrant liabilities" } } }, "localname": "IncreaseDecreaseInDerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in current assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r767", "r789" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r5" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "us-gaap_IncreaseDecreaseInOtherOperatingAssets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r5" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InternalRevenueServiceIRSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.", "label": "Internal Revenue Service (IRS) [Member]" } } }, "localname": "InternalRevenueServiceIRSMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": { "auth_ref": [ "r111" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.", "label": "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium", "negatedLabel": "Accretion of discount and amortization of premiums on marketable securities" } } }, "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r567", "r584", "r585", "r586", "r587", "r675", "r676" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r608", "r610", "r611", "r612", "r615", "r672", "r674", "r678", "r681", "r682", "r691", "r692", "r694", "r695", "r696", "r697", "r698", "r753" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textualB5161F24-A199-4D9A-9D11-680B80832079", "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-businessA333C5D9-19D0-4567-932F-9815DE5E9A16", "http://pyxisoncology.com/20230331/role/statement-note-3-merger", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r608", "r610", "r611", "r612", "r615", "r672", "r674", "r678", "r681", "r682", "r691", "r692", "r694", "r695", "r696", "r697", "r698", "r753" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textualB5161F24-A199-4D9A-9D11-680B80832079", "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-businessA333C5D9-19D0-4567-932F-9815DE5E9A16", "http://pyxisoncology.com/20230331/role/statement-note-3-merger", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r862" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-lease-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r491" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-note-6-lease-maturity-of-operating-lease-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "totalLabel": "Total undiscounted future lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-lease-maturity-of-operating-lease-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r491" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-note-6-lease-maturity-of-operating-lease-details": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Year ending December 31, 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-lease-maturity-of-operating-lease-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r491" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-lease-maturity-of-operating-lease-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r486" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-lease" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r27", "r191", "r277", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r451", "r452", "r453", "r474", "r624", "r718", "r761", "r818", "r867", "r868" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "us-gaap_Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r104", "r141", "r558", "r749", "r794", "r812", "r860" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r29", "r160", "r191", "r277", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r451", "r452", "r453", "r474", "r749", "r818", "r867", "r868" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r859" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-measurement-inputs-and-valuation-techniques-of-warrants-details" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r859" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-measurement-inputs-and-valuation-techniques-of-warrants-details" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r859" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-measurement-inputs-and-valuation-techniques-of-warrants-details" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r859" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-measurement-inputs-and-valuation-techniques-of-warrants-details" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r469" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-measurement-inputs-and-valuation-techniques-of-warrants-details" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-measurement-inputs-and-valuation-techniques-of-warrants-details" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r822" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r187" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r187" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r115", "r116", "r117" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r106", "r117", "r144", "r158", "r175", "r178", "r183", "r191", "r200", "r202", "r203", "r205", "r206", "r210", "r211", "r217", "r228", "r236", "r238", "r240", "r277", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r465", "r474", "r562", "r646", "r663", "r664", "r719", "r759", "r818" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonmonetaryTransactionTypeAxis": { "auth_ref": [ "r492", "r493", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748" ], "lang": { "en-us": { "role": { "documentation": "Information by nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange.", "label": "Nonmonetary Transaction Type [Axis]" } } }, "localname": "NonmonetaryTransactionTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_NonmonetaryTransactionTypeDomain": { "auth_ref": [ "r492", "r493", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748" ], "lang": { "en-us": { "role": { "documentation": "Identifies the nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange.", "label": "Nonmonetary Transaction Type [Domain]" } } }, "localname": "NonmonetaryTransactionTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r801" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "us-gaap_NumberOfOperatingSegments", "terseLabel": "Number of Operating Segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9" ], "xbrltype": "integerItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies2BD6C28F-50E7-4037-A60B-045979707453", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "us-gaap_OperatingExpenses", "terseLabel": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r228", "r236", "r238", "r240", "r719" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r861" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "us-gaap_OperatingLeaseExpense", "terseLabel": "Operating Lease, Expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-6-lease-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r488" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Total lease liabilities", "terseLabel": "Operating Lease, Liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-6-lease-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-6-lease-maturity-of-operating-lease-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r488" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Lease liabilities, current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r488" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Lease liabilities, less current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r487" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Right-of-use assets", "terseLabel": "Operating Lease, Right-of-Use Asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-6-lease-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r790" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.", "label": "Non-cash lease expense" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r490", "r740" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent", "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-lease-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r69" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "us-gaap_OperatingLossCarryforwards", "terseLabel": "Operating Loss Carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r92", "r133", "r581", "r582" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business", "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-businessA333C5D9-19D0-4567-932F-9815DE5E9A16" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-accrued-liabilities-10q-details": { "order": 0.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-accrued-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other accrued liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-accrued-liabilities-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-accrued-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r164" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of other commitment.", "label": "Other Commitments [Axis]" } } }, "localname": "OtherCommitmentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-10-commitments-and-contingencies", "http://pyxisoncology.com/20230331/role/statement-note-10-commitments-and-contingencies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-commitments-and-contingencies", "http://pyxisoncology.com/20230331/role/statement-note-9-commitments-and-contingencies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other future obligation.", "label": "Other Commitments [Domain]" } } }, "localname": "OtherCommitmentsDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-10-commitments-and-contingencies", "http://pyxisoncology.com/20230331/role/statement-note-10-commitments-and-contingencies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-commitments-and-contingencies", "http://pyxisoncology.com/20230331/role/statement-note-9-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r11", "r23", "r176", "r179", "r184", "r475", "r476", "r481", "r548", "r563", "r785", "r786" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "terseLabel": "Other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r173", "r174", "r273" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Unrealized gain on marketable securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r117" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "us-gaap_OtherNoncashIncomeExpense", "negatedLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r112" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r39" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "us-gaap_PaymentsOfFinancingCosts", "negatedLabel": "Payments of financing costs" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities": { "auth_ref": [ "r39" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for financing costs associated with business combinations.", "label": "us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities", "negatedLabel": "Payments of transaction costs", "terseLabel": "Payments of Merger Related Costs, Financing Activities" } } }, "localname": "PaymentsOfMergerRelatedCostsFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r804" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "us-gaap_PaymentsToAcquireMarketableSecurities", "negatedLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r114" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r355", "r356", "r357", "r363", "r364", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r732" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-13-401k-plan" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-schedule-of-valuation-assumptions-of-stock-options-details" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-schedule-of-valuation-assumptions-of-stock-options-details" ], "xbrltype": "domainItemType" }, "us-gaap_PolicyTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "localname": "PolicyTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockConvertibleConversionRatio": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted.", "label": "Conversion Ratio", "terseLabel": "Preferred Stock, Convertible, Conversion Ratio" } } }, "localname": "PreferredStockConvertibleConversionRatio", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-summary-of-convertible-preferred-stock-details", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-summary-of-convertible-preferred-stock-details" ], "xbrltype": "pureItemType" }, "us-gaap_PreferredStockConvertibleSharesIssuable": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "Number of common shares issuable upon conversion of preferred stock.", "label": "Common Stock, Shares (in shares)" } } }, "localname": "PreferredStockConvertibleSharesIssuable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-summary-of-convertible-preferred-stock-details", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-summary-of-convertible-preferred-stock-details" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [ "r751", "r752", "r755", "r756", "r757", "r758", "r879", "r882" ], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r97", "r326" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "us-gaap_PreferredStockParOrStatedValuePerShare", "terseLabel": "Preferred Stock, Par or Stated Value Per Share (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r97", "r626" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "us-gaap_PreferredStockSharesAuthorized", "terseLabel": "Preferred Stock, Shares Authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r97", "r626", "r644", "r882", "r883" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding (in shares)", "terseLabel": "Preferred Stock, Shares Outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-summary-of-convertible-preferred-stock-details", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-summary-of-convertible-preferred-stock-details" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r784" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-prepaid-expenses-and-other-current-assets-10q-details": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-prepaid-expenses-and-other-current-assets-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-prepaid-expenses-and-other-current-assets-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-prepaid-expenses-and-other-current-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r711", "r723", "r815" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-prepaid-expenses-and-other-current-assets-10q-details": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-prepaid-expenses-and-other-current-assets-details": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid insurance expenses" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-prepaid-expenses-and-other-current-assets-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-prepaid-expenses-and-other-current-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events", "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r4" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from common stock issuance to Lincoln Park", "terseLabel": "Proceeds from Issuance of Common Stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r4" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details": { "order": 1.0, "parentTag": "pyxs_ProceedsFromBusinessCombinationAndPrivateOffering", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details": { "order": 2.0, "parentTag": "pyxs_ProceedsFromBusinessCombinationAndPrivateOffering", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Cash - Private offering", "terseLabel": "Cash - Private offering" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r4", "r589" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "us-gaap_ProceedsFromIssuanceOrSaleOfEquity", "terseLabel": "Proceeds from Issuance or Sale of Equity" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Sales of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "auth_ref": [ "r37" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.", "label": "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments", "terseLabel": "Proceeds from Sale, Maturity and Collection of Investments" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textualB5161F24-A199-4D9A-9D11-680B80832079", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r113" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Sales of property and equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r4", "r21" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies2BD6C28F-50E7-4037-A60B-045979707453", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-10-q-", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-10-q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-details" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisposals": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "us-gaap_PropertyPlantAndEquipmentDisposals", "terseLabel": "Property, Plant and Equipment, Disposals" } } }, "localname": "PropertyPlantAndEquipmentDisposals", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-10-q-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r120", "r162", "r561" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-10q-details": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-details": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r7", "r551", "r561", "r749" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-10q-details": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net", "totalLabel": "Total property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r7", "r149", "r152", "r559" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-10-q-tables", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r120" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies2BD6C28F-50E7-4037-A60B-045979707453", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-10-q-", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-10-q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife", "terseLabel": "Property, Plant and Equipment, Useful Life (Year)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9" ], "xbrltype": "durationItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r365", "r496", "r497", "r619", "r620", "r621", "r622", "r623", "r643", "r645", "r671" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party, Type [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r496", "r497", "r866" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r365", "r496", "r497", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r619", "r620", "r621", "r622", "r623", "r643", "r645", "r671", "r866" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party, Type [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r788" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details": { "order": 2.0, "parentTag": "pyxs_ProceedsFromBusinessCombinationAndPrivateOffering", "weight": -1.0 }, "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details": { "order": 0.0, "parentTag": "pyxs_ProceedsFromBusinessCombinationAndPrivateOffering", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.", "label": "us-gaap_RepaymentsOfDebt", "negatedLabel": "Less: BCAC's Extension and Working Capital Notes repayment in 2022", "terseLabel": "Repayments of Debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textualB5161F24-A199-4D9A-9D11-680B80832079", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r91", "r421", "r875" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies2BD6C28F-50E7-4037-A60B-045979707453", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-stockbased-compensation-expense-details", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-stockbased-compensation-expense-details" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchMember": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.", "label": "Research Tax Credit Carryforward [Member]" } } }, "localname": "ResearchMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r161" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textualB5161F24-A199-4D9A-9D11-680B80832079", "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-businessA333C5D9-19D0-4567-932F-9815DE5E9A16", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-details" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.", "label": "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings", "terseLabel": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings" } } }, "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r101", "r126", "r557", "r574", "r579", "r593", "r627", "r749" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Accumulated deficit", "terseLabel": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets", "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textualB5161F24-A199-4D9A-9D11-680B80832079" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAppropriatedMember": { "auth_ref": [ "r56", "r100" ], "lang": { "en-us": { "role": { "documentation": "A segregation of retained earnings which is unavailable for dividend distribution. Includes also retained earnings appropriated for loss contingencies.", "label": "Retained Earnings, Appropriated [Member]" } } }, "localname": "RetainedEarningsAppropriatedMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r156", "r197", "r198", "r199", "r201", "r209", "r211", "r278", "r281", "r412", "r413", "r414", "r440", "r441", "r454", "r456", "r457", "r459", "r463", "r570", "r572", "r595", "r882" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r154", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r709" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "us-gaap_SaleOfStockConsiderationReceivedOnTransaction", "terseLabel": "Sale of Stock, Consideration Received on Transaction" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textualB5161F24-A199-4D9A-9D11-680B80832079", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events", "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction", "terseLabel": "Sale of Stock, Number of Shares Issued in Transaction (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textualB5161F24-A199-4D9A-9D11-680B80832079", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "us-gaap_SaleOfStockPricePerShare", "terseLabel": "Sale of Stock, Price Per Share (in dollars per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textualB5161F24-A199-4D9A-9D11-680B80832079", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-10-q-tables", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-net-loss-per-share-tables", "http://pyxisoncology.com/20230331/role/statement-note-12-net-loss-per-share-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r71", "r72" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-tables", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r65" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-tables", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r130" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r19", "r20", "r61" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Activity [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r129" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.", "label": "Schedule of Stockholders Equity [Table Text Block]" } } }, "localname": "ScheduleOfStockholdersEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-tables", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r739", "r852" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r230", "r231", "r232", "r233", "r234", "r235", "r241", "r720" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [ "r781", "r782", "r821" ], "lang": { "en-us": { "role": { "documentation": "Series B preferred stock.", "label": "Series B Preferred Stock [Member]" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-summary-of-convertible-preferred-stock-details", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-summary-of-convertible-preferred-stock-details" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesCPreferredStockMember": { "auth_ref": [ "r781", "r782", "r821" ], "lang": { "en-us": { "role": { "documentation": "Series C preferred stock.", "label": "Series C Preferred Stock [Member]" } } }, "localname": "SeriesCPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-summary-of-convertible-preferred-stock-details", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-summary-of-convertible-preferred-stock-details" ], "xbrltype": "domainItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r6" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "us-gaap_SeveranceCosts1", "terseLabel": "Severance Costs" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r5" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensation", "verboseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r736" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "negatedLabel": "Restricted stock units forfeited, shares (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Restricted stock awards granted, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "negatedLabel": "Restricted stock awards vested, shares (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r397" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Expected dividend" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-schedule-of-valuation-assumptions-of-stock-options-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r403" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-schedule-of-valuation-assumptions-of-stock-options-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected volatility, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-schedule-of-valuation-assumptions-of-stock-options-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected volatility, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-schedule-of-valuation-assumptions-of-stock-options-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-schedule-of-valuation-assumptions-of-stock-options-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-schedule-of-valuation-assumptions-of-stock-options-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Exercise of common stock restricted awards - 2022 (pre-Closing) (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r15", "r16" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r738" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r388" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "negatedLabel": "Options Cancelled, shares (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue": { "auth_ref": [ "r396" ], "lang": { "en-us": { "role": { "documentation": "The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r386" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Options Granted, shares (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r396" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r58" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Outstanding, intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r382", "r383" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Outstanding, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r382", "r383" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Outstanding, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r399" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested and exercisable, intrinsic value", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested and exercisable, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested and exercisable, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r398" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested and expected to vest, intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested and expected to vest, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested and expected to vest, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued under share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": { "auth_ref": [ "r850" ], "lang": { "en-us": { "role": { "documentation": "Number of shares purchased for issuance under share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r378", "r379", "r380", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r402", "r403", "r404", "r405", "r406" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-schedule-of-valuation-assumptions-of-stock-options-details", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r387" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Options Exercised, weighted average exercise price (in dollars per share)", "terseLabel": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r388" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Options Cancelled, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r386" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Options Granted, weighted average exercise price (in dollars per share)", "terseLabel": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-Based Payment Arrangement, Tranche One [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-Based Payment Arrangement, Tranche Two [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheTwoMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r375", "r381", "r400", "r401", "r402", "r403", "r406", "r415", "r416", "r417", "r418" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-exercise-price-range-of-options-details" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Exercise Price Range [Domain]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-exercise-price-range-of-options-details" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Lower Range Limit (in dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-exercise-price-range-of-options-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.", "label": "Shares Exercisable (in shares)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-exercise-price-range-of-options-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "auth_ref": [ "r59" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.", "label": "Shares Outstanding (in shares)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-exercise-price-range-of-options-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Upper Range Limit (in dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-exercise-price-range-of-options-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by supplier.", "label": "Supplier [Axis]" } } }, "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies2BD6C28F-50E7-4037-A60B-045979707453" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received.", "label": "Supplier [Domain]" } } }, "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies2BD6C28F-50E7-4037-A60B-045979707453" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r823" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r737" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected term (years) (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-schedule-of-valuation-assumptions-of-stock-options-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Outstanding, term (Year)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested and exercisable, term (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested and expected to vest, term (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value (in dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": { "auth_ref": [ "r60" ], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.", "label": "Exercisable, Weighted Average Exercise Price (in dollars per share)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-exercise-price-range-of-options-details" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Exercisable, Weighted Average Remaining Contractual Term (Year)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-exercise-price-range-of-options-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "auth_ref": [ "r59" ], "lang": { "en-us": { "role": { "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.", "label": "Outstanding, Weighted Average Exercise Price (in dollars per share)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-exercise-price-range-of-options-details" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Outstanding, Weighted Average Remaining Contractual Term (Year)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-exercise-price-range-of-options-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "us-gaap_SharesOutstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r142", "r143", "r783" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term investments", "terseLabel": "Short-Term Investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-10q-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r118", "r189" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies2BD6C28F-50E7-4037-A60B-045979707453" ], "xbrltype": "textBlockItemType" }, "us-gaap_SoftwareDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Internally developed software for sale, licensing or long-term internal use.", "label": "Software Development [Member]" } } }, "localname": "SoftwareDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies2BD6C28F-50E7-4037-A60B-045979707453", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r155", "r166", "r167", "r168", "r191", "r215", "r216", "r218", "r220", "r226", "r227", "r277", "r299", "r301", "r302", "r303", "r306", "r307", "r326", "r327", "r331", "r334", "r341", "r474", "r589", "r590", "r591", "r592", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r626", "r647", "r665", "r699", "r700", "r701", "r702", "r703", "r764", "r792", "r799" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-summary-of-common-stock-reserved-for-issuance-details", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-summary-of-convertible-preferred-stock-details", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-summary-of-common-stock-reserved-for-issuance-details", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-summary-of-convertible-preferred-stock-details" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r11", "r33", "r156", "r181", "r182", "r183", "r197", "r198", "r199", "r201", "r209", "r211", "r225", "r278", "r281", "r343", "r412", "r413", "r414", "r440", "r441", "r454", "r455", "r456", "r457", "r458", "r459", "r463", "r475", "r477", "r478", "r479", "r480", "r481", "r495", "r570", "r571", "r572", "r595", "r665" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r197", "r198", "r199", "r225", "r534", "r584", "r606", "r618", "r619", "r620", "r621", "r622", "r623", "r626", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r639", "r640", "r641", "r642", "r643", "r645", "r648", "r649", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r665", "r754" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited-parentheticals", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets-parentheticals", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity-parentheticals", "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business", "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textualB5161F24-A199-4D9A-9D11-680B80832079", "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-businessA333C5D9-19D0-4567-932F-9815DE5E9A16", "http://pyxisoncology.com/20230331/role/statement-note-10-commitments-and-contingencies", "http://pyxisoncology.com/20230331/role/statement-note-10-commitments-and-contingencies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-10-income-taxes", "http://pyxisoncology.com/20230331/role/statement-note-10-income-taxes-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-reconciliation-of-effective-income-tax-rate-details", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-schedule-of-unrecognized-tax-benefits-details", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-tables", "http://pyxisoncology.com/20230331/role/statement-note-11-net-loss-per-share", "http://pyxisoncology.com/20230331/role/statement-note-11-net-loss-per-share-antidilutive-securities-details", "http://pyxisoncology.com/20230331/role/statement-note-11-net-loss-per-share-tables", "http://pyxisoncology.com/20230331/role/statement-note-12-net-loss-per-share", "http://pyxisoncology.com/20230331/role/statement-note-12-net-loss-per-share-antidilutive-securities-details", "http://pyxisoncology.com/20230331/role/statement-note-12-net-loss-per-share-tables", "http://pyxisoncology.com/20230331/role/statement-note-12-subsequent-event", "http://pyxisoncology.com/20230331/role/statement-note-13-401k-plan", "http://pyxisoncology.com/20230331/role/statement-note-13-401k-plan-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events", "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies2BD6C28F-50E7-4037-A60B-045979707453", "http://pyxisoncology.com/20230331/role/statement-note-3-merger", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-tables", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-tables", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-10q", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-10q-tables", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-tables", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-10-q-", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-10-q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-10-q-tables", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-accrued-liabilities-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-accrued-liabilities-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-prepaid-expenses-and-other-current-assets-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-prepaid-expenses-and-other-current-assets-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-tables", "http://pyxisoncology.com/20230331/role/statement-note-6-lease", "http://pyxisoncology.com/20230331/role/statement-note-6-lease-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-6-lease-maturity-of-operating-lease-details", "http://pyxisoncology.com/20230331/role/statement-note-6-lease-tables", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-summary-of-common-stock-reserved-for-issuance-details", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-summary-of-convertible-preferred-stock-details", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-tables", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-measurement-inputs-and-valuation-techniques-of-warrants-details", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-tables", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-summary-of-common-stock-reserved-for-issuance-details", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-summary-of-convertible-preferred-stock-details", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-tables", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-stockbased-compensation-expense-details", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-tables", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-commitments-and-contingencies", "http://pyxisoncology.com/20230331/role/statement-note-9-commitments-and-contingencies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-exercise-price-range-of-options-details", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-schedule-of-valuation-assumptions-of-stock-options-details", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-stockbased-compensation-expense-details", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-tables", "http://pyxisoncology.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r197", "r198", "r199", "r225", "r534", "r584", "r606", "r618", "r619", "r620", "r621", "r622", "r623", "r626", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r639", "r640", "r641", "r642", "r643", "r645", "r648", "r649", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r665", "r754" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited-parentheticals", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets-parentheticals", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity-parentheticals", "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business", "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-business-details-textualB5161F24-A199-4D9A-9D11-680B80832079", "http://pyxisoncology.com/20230331/role/statement-note-1-organization-and-description-of-the-businessA333C5D9-19D0-4567-932F-9815DE5E9A16", "http://pyxisoncology.com/20230331/role/statement-note-10-commitments-and-contingencies", "http://pyxisoncology.com/20230331/role/statement-note-10-commitments-and-contingencies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-10-income-taxes", "http://pyxisoncology.com/20230331/role/statement-note-10-income-taxes-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-reconciliation-of-effective-income-tax-rate-details", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-schedule-of-deferred-tax-assets-and-liabilities-details", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-schedule-of-unrecognized-tax-benefits-details", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-tables", "http://pyxisoncology.com/20230331/role/statement-note-11-net-loss-per-share", "http://pyxisoncology.com/20230331/role/statement-note-11-net-loss-per-share-antidilutive-securities-details", "http://pyxisoncology.com/20230331/role/statement-note-11-net-loss-per-share-tables", "http://pyxisoncology.com/20230331/role/statement-note-12-net-loss-per-share", "http://pyxisoncology.com/20230331/role/statement-note-12-net-loss-per-share-antidilutive-securities-details", "http://pyxisoncology.com/20230331/role/statement-note-12-net-loss-per-share-tables", "http://pyxisoncology.com/20230331/role/statement-note-12-subsequent-event", "http://pyxisoncology.com/20230331/role/statement-note-13-401k-plan", "http://pyxisoncology.com/20230331/role/statement-note-13-401k-plan-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events", "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies2BD6C28F-50E7-4037-A60B-045979707453", "http://pyxisoncology.com/20230331/role/statement-note-3-merger", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-tables", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-tables", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-10q", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-10q-tables", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-tables", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-10-q-", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-10-q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-10-q-tables", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-accrued-liabilities-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-accrued-liabilities-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-prepaid-expenses-and-other-current-assets-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-prepaid-expenses-and-other-current-assets-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-summary-of-property-plant-and-equipment-details", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-tables", "http://pyxisoncology.com/20230331/role/statement-note-6-lease", "http://pyxisoncology.com/20230331/role/statement-note-6-lease-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-6-lease-maturity-of-operating-lease-details", "http://pyxisoncology.com/20230331/role/statement-note-6-lease-tables", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-summary-of-common-stock-reserved-for-issuance-details", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-summary-of-convertible-preferred-stock-details", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-tables", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-measurement-inputs-and-valuation-techniques-of-warrants-details", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-tables", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-summary-of-common-stock-reserved-for-issuance-details", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-summary-of-convertible-preferred-stock-details", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-tables", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-stockbased-compensation-expense-details", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-tables", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-commitments-and-contingencies", "http://pyxisoncology.com/20230331/role/statement-note-9-commitments-and-contingencies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-exercise-price-range-of-options-details", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-schedule-of-valuation-assumptions-of-stock-options-details", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-stockbased-compensation-expense-details", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-tables", "http://pyxisoncology.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StockCompensationPlanMember": { "auth_ref": [ "r800" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.", "label": "Share-Based Payment Arrangement [Member]" } } }, "localname": "StockCompensationPlanMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-12-net-loss-per-share-antidilutive-securities-details" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r42", "r43", "r44" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Common stock issuance to Lincoln Park for commitment fees" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r97", "r98", "r126" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Common stock of BCAC (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r11", "r97", "r98", "r126", "r589", "r665", "r700" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Shares issued in private offering (in shares)", "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r11", "r97", "r98", "r126" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Vesting of restricted stock units (in shares)", "verboseLabel": "Vesting of restricted stock awards (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r11", "r97", "r98", "r126", "r387" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Exercise of common stock options (in shares)", "negatedLabel": "Options Exercised, shares (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-summary-of-activities-under-the-plans-details" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r11", "r97", "r98", "r126", "r595", "r665", "r700", "r760" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Private offering, net of transaction costs of $659" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "us-gaap_StockIssuedDuringPeriodValueOther", "terseLabel": "Stock Issued During Period, Value, Other" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r11", "r126" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Vesting of restricted stock units", "verboseLabel": "Vesting of restricted stock awards" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r11", "r33", "r126" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRedeemedOrCalledDuringPeriodShares": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Number of stock bought back by the entity at the exercise price or redemption price.", "label": "us-gaap_StockRedeemedOrCalledDuringPeriodShares", "terseLabel": "Stock Redeemed or Called During Period, Shares (in shares)" } } }, "localname": "StockRedeemedOrCalledDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRedeemedOrCalledDuringPeriodValue": { "auth_ref": [ "r11" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.", "label": "us-gaap_StockRedeemedOrCalledDuringPeriodValue", "terseLabel": "Stock Redeemed or Called During Period, Value" } } }, "localname": "StockRedeemedOrCalledDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r98", "r102", "r103", "r119", "r628", "r644", "r666", "r667", "r749", "r761", "r794", "r812", "r860", "r882" ], "calculation": { "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 }, "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "us-gaap_StockholdersEquity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r125", "r190", "r325", "r327", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r340", "r343", "r461", "r668", "r670", "r704" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "Equity [Text Block]" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1", "terseLabel": "Stockholders' Equity Note, Stock Split, Conversion Ratio" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "pureItemType" }, "us-gaap_StockholdersEquityPolicyTextBlock": { "auth_ref": [ "r8", "r669" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.", "label": "Stockholders' Equity, Policy [Policy Text Block]" } } }, "localname": "StockholdersEquityPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r482", "r500" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events", "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r482", "r500" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events", "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r482", "r500" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events", "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r499", "r501" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-12-subsequent-event", "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events", "http://pyxisoncology.com/20230331/role/statement-note-14-subsequent-events-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-schedule-of-elements-of-business-combination-details", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants", "http://pyxisoncology.com/20230331/role/statement-note-8-public-and-private-warrants-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r778" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-10-q-" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplierConcentrationRiskMember": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.", "label": "Supplier Concentration Risk [Member]" } } }, "localname": "SupplierConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies-details-textual7D6D06FA-0969-409C-A7DF-3DF6C1F20DA9", "http://pyxisoncology.com/20230331/role/statement-note-2-summary-of-significant-accounting-policies2BD6C28F-50E7-4037-A60B-045979707453" ], "xbrltype": "domainItemType" }, "us-gaap_TableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "localname": "TableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-tables", "http://pyxisoncology.com/20230331/role/statement-note-11-net-loss-per-share-tables", "http://pyxisoncology.com/20230331/role/statement-note-12-net-loss-per-share-tables", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-10q-tables", "http://pyxisoncology.com/20230331/role/statement-note-3-merger-tables", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-10q-tables", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-tables", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-10-q-tables", "http://pyxisoncology.com/20230331/role/statement-note-5-balance-sheet-components-tables", "http://pyxisoncology.com/20230331/role/statement-note-6-lease-tables", "http://pyxisoncology.com/20230331/role/statement-note-6-stockholders-equity-tables", "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-tables", "http://pyxisoncology.com/20230331/role/statement-note-7-stockholders-equity-tables", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-tables", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-tables" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r69" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "us-gaap_TaxCreditCarryforwardAmount", "terseLabel": "Tax Credit Carryforward, Amount" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name [Domain]" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes", "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r324", "r339", "r460", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r564", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r808", "r809", "r810", "r811" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-details" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentDebtSecuritiesMember": { "auth_ref": [ "r876" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by the United States government.", "label": "US Government Debt Securities [Member]" } } }, "localname": "USGovernmentDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r716", "r730", "r732", "r876" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-estimated-fair-value-of-marketable-securities-and-gross-unrealized-holding-gains-and-losses-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-10q-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-financial-instruments-on-recurring-basis-details" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r423", "r429" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "us-gaap_UnrecognizedTaxBenefits", "periodEndLabel": "Gross unrecognized tax benefit at December 31", "periodStartLabel": "Gross unrecognized tax benefit at January 1" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-schedule-of-unrecognized-tax-benefits-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r430" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Additions for tax provision taken in the current year" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-schedule-of-unrecognized-tax-benefits-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r50", "r51", "r52", "r146", "r147", "r150", "r151" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r433" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount", "terseLabel": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r845", "r846", "r847", "r848" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-8-equity-plans-and-related-equity-activities-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities", "http://pyxisoncology.com/20230331/role/statement-note-9-equity-plans-and-related-equity-activities-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [ "r751", "r752", "r755", "r756", "r757", "r758" ], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-11-net-loss-per-share-antidilutive-securities-details", "http://pyxisoncology.com/20230331/role/statement-note-12-net-loss-per-share-antidilutive-securities-details", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-10q", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-10q-details-textual", "http://pyxisoncology.com/20230331/role/statement-note-4-fair-value-measurement-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "us-gaap_WarrantsAndRightsOutstanding", "terseLabel": "Warrants and Rights Outstanding" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Measurement Input" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-note-7-public-and-private-warrants-measurement-inputs-and-valuation-techniques-of-warrants-details" ], "xbrltype": "decimalItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r214", "r220" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted-average common shares used to compute net loss per share, basic and diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://pyxisoncology.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://pyxisoncology.com/20230331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3)(i))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org//805/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org//810/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org//606/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org//260/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2C", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(3)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(4)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "https://asc.fasb.org//715/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org//718/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.C.Q3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org//740/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//842-20/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "845", "URI": "https://asc.fasb.org//1943274/2147482864/845-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "845", "URI": "https://asc.fasb.org//1943274/2147482864/845-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(2)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(f)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(f)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(f)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(h)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(g)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(h)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(4)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(15))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(i)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column G))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13A(Column E))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13B(Column E))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13C(Column H))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "47", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "845", "URI": "https://asc.fasb.org//1943274/2147482819/845-10-05-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "845", "URI": "https://asc.fasb.org//1943274/2147482819/845-10-05-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "845", "URI": "https://asc.fasb.org//1943274/2147482819/845-10-05-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "845", "URI": "https://asc.fasb.org//1943274/2147482819/845-10-05-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "845", "URI": "https://asc.fasb.org//1943274/2147482819/845-10-05-5", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "845", "URI": "https://asc.fasb.org//1943274/2147482819/845-10-05-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "845", "URI": "https://asc.fasb.org//1943274/2147482819/845-10-05-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "845", "URI": "https://asc.fasb.org//1943274/2147482819/845-10-05-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r762": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r763": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r771": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r772": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r773": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r774": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r775": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r776": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r777": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r778": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "https://asc.fasb.org//210/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r780": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r781": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r782": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r783": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r784": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r785": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r786": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r787": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r788": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r789": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r790": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r791": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(b))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r792": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r793": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r794": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r795": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r796": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r797": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r798": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r799": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r800": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r801": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r802": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r803": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r804": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r805": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r806": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r807": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r808": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r809": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r810": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r811": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r812": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r813": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r814": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r815": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r816": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r817": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r818": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r819": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r820": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r821": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r822": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r823": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r824": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r825": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r826": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r827": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r828": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r829": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r830": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r831": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r832": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r833": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r834": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r835": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r836": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r837": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r838": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r839": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r840": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r841": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r842": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r843": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r844": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r845": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r846": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r847": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r848": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r849": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r850": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r851": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r852": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r853": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r854": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r855": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r856": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r857": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r858": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r859": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r860": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r861": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r862": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r863": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r864": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r865": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r866": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r867": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r868": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r869": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r870": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r871": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r872": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r873": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r874": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r875": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r876": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r877": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r878": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r879": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r880": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(3)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r881": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r882": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r883": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" }